<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Citicoline for treating people with acute ischemic stroke - Martí-Carvajal, AJ - 2020 | Cochrane Library</title> <meta content="Citicoline for treating people with acute ischemic stroke - Martí-Carvajal, AJ - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013066.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Citicoline for treating people with acute ischemic stroke - Martí-Carvajal, AJ - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013066.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013066.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Citicoline for treating people with acute ischemic stroke" name="citation_title"/> <meta content="Arturo J Martí-Carvajal" name="citation_author"/> <meta content="arturo.marti.carvajal@gmail.com" name="citation_author_email"/> <meta content="Claudia Valli" name="citation_author"/> <meta content="Biomedical Research Institute Sant Pau (IIB Sant Pau)" name="citation_author_institution"/> <meta content="Cristina Elena Martí-Amarista" name="citation_author"/> <meta content="Northwell Health Southside Hospital" name="citation_author_institution"/> <meta content="Ivan Solà" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Joan Martí-Fàbregas" name="citation_author"/> <meta content="Hospital de la Santa Creu i Sant Pau" name="citation_author_institution"/> <meta content="Xavier Bonfill Cosp" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD013066.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013066.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013066.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013066.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Activities of Daily Living; Acute Disease; Bias; Brain Ischemia [complications]; Cause of Death; Cytidine Diphosphate Choline [adverse effects, *therapeutic use]; Nootropic Agents [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Recovery of Function; Stroke [*drug therapy, etiology, mortality]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013066.pub2&amp;doi=10.1002/14651858.CD013066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013066\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013066\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013066.pub2",title:"Citicoline for treating people with acute ischemic stroke",firstPublishedDate:"Aug 29, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013066.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013066.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013066.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013066.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013066.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013066.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013066.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013066.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013066.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013066.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9800 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013066.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/appendices#CD013066-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/supinfo/CD013066StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/supinfo/CD013066StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Citicoline for treating people with acute ischemic stroke</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#CD013066-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Arturo J Martí-Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#CD013066-cr-0005">Claudia Valli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#CD013066-cr-0006">Cristina Elena Martí-Amarista</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#CD013066-cr-0007">Ivan Solà</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#CD013066-cr-0008">Joan Martí-Fàbregas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information#CD013066-cr-0009">Xavier Bonfill Cosp</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information/en#CD013066-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013066.pub2">https://doi.org/10.1002/14651858.CD013066.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013066-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013066-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013066-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013066-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013066-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013066-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013066-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013066-abs-0001" lang="en"> <section id="CD013066-sec-0001"> <h3 class="title" id="CD013066-sec-0001">Background</h3> <p>Stroke is one of the leading causes of long‐lasting disability and mortality and its global burden has increased in the past two decades. Several therapies have been proposed for the recovery from, and treatment of, ischemic stroke. One of them is citicoline. This review assessed the benefits and harms of citicoline for treating patients with acute ischemic stroke. </p> </section> <section id="CD013066-sec-0002"> <h3 class="title" id="CD013066-sec-0002">Objectives</h3> <p>To assess the clinical benefits and harms of citicoline compared with placebo or any other control for treating people with acute ischemic stroke. </p> </section> <section id="CD013066-sec-0003"> <h3 class="title" id="CD013066-sec-0003">Search methods</h3> <p>We searched in the Cochrane Stroke Group Trials Register, CENTRAL, MEDLINE Ovid, Embase Ovid, LILACS until 29 January 2020. We searched the World Health Organization Clinical Trials Search Portal and ClinicalTrials.gov. Additionally, we also reviewed reference lists of the retrieved publications and review articles, and searched the websites of the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). </p> </section> <section id="CD013066-sec-0004"> <h3 class="title" id="CD013066-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) in any setting including participants with acute ischemic stroke. Trials were eligible for inclusion if they compared citicoline versus placebo or no intervention. </p> </section> <section id="CD013066-sec-0005"> <h3 class="title" id="CD013066-sec-0005">Data collection and analysis</h3> <p>We selected RCTs, assessed the risk of bias in seven domains, and extracted data by duplicate. Our primary outcomes of interest were all‐cause mortality and the degree of disability or dependence in daily activities at 90 days. We estimated risk ratios (RRs) for dichotomous outcomes. We measured statistical heterogeneity using the I² statistic. We conducted our analyses using the fixed‐effect and random‐effects model meta‐analyses. We assessed the overall quality of evidence for six pre‐specified outcomes using the GRADE approach. </p> </section> <section id="CD013066-sec-0006"> <h3 class="title" id="CD013066-sec-0006">Main results</h3> <p>We identified 10 RCTs including 4281 participants. In all these trials, citicoline was given either orally, intravenously, or a combination of both compared with placebo or standard care therapy. Citicoline doses ranged between 500 mg and 2000 mg per day. We assessed all the included trials as having high risk of bias. Drug companies sponsored six trials. </p> <p>A pooled analysis of eight trials indicates there may be little or no difference in all‐cause mortality comparing citicoline with placebo (17.3% versus 18.5%; RR 0.94, 95% CI 0.83 to 1.07; I² = 0%; low‐quality evidence due to risk of bias). Four trials showed that citicoline may not increase the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, according to the Rankin Scale (21.72% versus 19.23%; RR 1.11, 95% CI 0.97 to 1.26; I² = 1%; low‐quality evidence due to risk of bias). </p> <p>Meta‐analysis of three trials indicates there may be little or no difference in serious cardiovascular adverse events comparing citicoline with placebo (8.83% versus 7.77%; RR 1.04, 95% CI 0.84 to 1.29; I² = 0%; low‐quality evidence due to risk of bias). Overall, either serious or non‐serious adverse events – central nervous system, gastrointestinal, musculoskeletal, etc. – were poorly reported and harms may have been underestimated. </p> <p>Four trials suggested that citicoline results in no difference in functional recovery, according to the Barthel Index, compared with placebo (32.78% versus 30.70%; RR 1.03, 95% CI 0.94 to 1.13; I² = 24%; low‐quality evidence due to risk of bias). Citicoline may not increase the proportion of patients with a minor impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale) (5 trials, 24.31% versus 22.44%; RR 1.08, 95% CI 0.96 to 1.21; I² = 27%, low‐quality evidence due to risk of bias). None of the included trials reported data on quality of life. </p> <p>A pre‐planned Trial Sequential Analysis suggested that no more trials may be needed for the primary outcomes. </p> </section> <section id="CD013066-sec-0007"> <h3 class="title" id="CD013066-sec-0007">Authors' conclusions</h3> <p>This review assessed the clinical benefits and harms of citicoline compared with placebo or any other standard treatment for people with acute ischemic stroke. The findings of the review suggest there may be little to no difference between citicoline and its controls regarding all‐cause mortality, disability or dependence in daily activities, functional recovery, neurological function and severe adverse events, based on low‐certainty evidence. None of the included trials assessed quality of life and the safety profile of citicoline remains unknown. The available evidence is of low quality due to either limitations in the design or execution of the trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013066-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013066-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013066-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013066-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013066-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013066-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013066-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013066-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013066-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013066-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013066-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013066-abs-0002" lang="en"> <h3>Citicoline for treating people with acute ischemic stroke</h3> <p><b>Review question</b><br/>What is the clinical benefit and harm of citicoline compared with placebo or other standard treatment for treating people with acute ischemic stroke? </p> <p><b>Background</b><br/>Acute ischemic stroke is defined as a sudden episode of disturbance of brain function caused by a blockage in the blood vessels of the brain. It is the leading cause of long‐lasting disability and the second major cause of death. Citicoline is a substance that may prevent the death of brain cells located close to the area of brain damage. </p> <p><b>Search date</b><br/>Searching was completed on 29 January 2020 </p> <p><b>Study characteristics</b><br/>We included randomized controlled trials, both published and unpublished. We did not apply any limitation by language, country, or study design. We included people (adults or children) with acute ischemic stroke irrespective of the underlying cause. Stroke was based on the clinical diagnosis confirmed with brain scans. We included trials that compared citicoline with placebo, usual care, or other usual treatment. </p> <p><b>Key results</b><br/>We identified 10 relevant trials that included 4281 participants; six trials were carried out in multiple centers and two were international. We considered most trials to be at high risk of bias and they included small numbers of participants. This raises the risk of over‐estimating benefits and under‐estimating harms. Trials tested citicoline given either by mouth or by injection. Citicoline did not seem to influence death or disability in daily activities, severe side‐effects, functional recovery, or neurological recovery. </p> <p><b>Quality of the evidence</b><br/>Risks of bias, imprecision, and outcome reporting bias all make the quality of evidence low. None of the included trials reported data on quality of life. Researchers poorly reported harms caused by citicoline, so the profile of harms remains unclear. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013066-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013066-sec-0104"></div> <h3 class="title" id="CD013066-sec-0105">Implications for practice</h3> <section id="CD013066-sec-0105"> <p>This review assessed the clinical benefits and harms of citicoline compared with placebo or any other standard treatment for people with acute ischemic stroke. The findings of the review suggest that, based on low‐certainty evidence, there may be little to no difference between citicoline and its controls regarding all‐cause mortality, disability or dependence in daily activities, functional recovery, neurological function and severe adverse events. None of the included trials assessed quality of life and the safety profile of citicoline remains unknown. </p> </section> <h3 class="title" id="CD013066-sec-0106">Implications for research</h3> <section id="CD013066-sec-0106"> <p>The harms profile of citicoline remains unknown, because the resulting evidence is of low quality due to limitations in the design and execution of the trials, the very low number of events, and the smallness of sample sizes, even after meta‐analysis. The results provided by the Trial Sequential Analysis methodology support the conclusions of the best quality clinical trials included in this Cochrane Review. The question is, is there a need for a new study when none of the included RCTs reached the top line of statistical significance; that is, the P value (alpha error), the fundamental component for calculating the sample size? Even for the most important primary outcome of this Cochrane Review, all‐cause mortality, the z‐curve reached the area of futility with a cumulative 65% of the sample size estimation for Trial Sequential Analysis (4345/6667). This Cochrane Review found no trial assessing quality of life. We do not believe that this lack of information on the quality of life outcome justifies a well‐powered randomized controlled trial comparing citicoline versus placebo in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (<a href="./references#CD013066-bbs2-0108" title="SPIRIT. Standard Protocol Items: Recommendations for Interventional Trials. www.spirit-statement.org/ (accessed 8 July 2020).">SPIRIT 2013</a>) and Consolidated Standards of Reporting Trials (<a href="./references#CD013066-bbs2-0039" title="CONSORT. Consolidated Standards of Reporting Trials. www.consort-statement.org/ (accessed 8 July 2020).">CONSORT 2010</a>) recommendations. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013066-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013066-sec-0008"></div> <div class="table" id="CD013066-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Citicoline compared with placebo or standard treatment for treating people with acute ischemic stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Citicoline compared with placebo or no intervention for treating people with acute ischemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acute ischemic stroke<br/><b>Settings:</b> either inpatients or outpatients<br/><b>Intervention:</b> citicoline<br/><b>Comparison:</b> placebo or standard treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Citicoline</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality (at any time of trial)</b><br/>Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>162 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/>(135 to 173) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.83 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4362<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability or dependence in daily activities</b> </p> <p>Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale) </p> <p>lower scores indicate better outcome</p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/>(219 to 284) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/>(0.97 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3668<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe adverse events</b> <br/>Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>166 per 1000</b><br/>(134 to 205) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/>(1.00 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3591<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This information corresponds to pooled analysis for the risk of severe cardiovascular adverse events. Trials reported number of adverse events instead of number of participants with adverse events. See <a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional recovery</b><br/>Patients with scores in the Barthel Index ≥ 95 points<br/>Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b><br/>(316 to 380) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/>(0.94 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3850<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a> reported this outcome using 50 points </p> <p><a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a> reported it with a range of points (85 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological function</b><br/>Patients with minor impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale)<br/>Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>244 per 1000</b><br/>(217 to 274) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/>(0.96 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3950<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (at the time of follow‐up)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trials assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Assumed risk is based on median control group risks in the meta‐analysis.<br/><sup>b</sup>Downgraded 2 levels for limitations in design and execution: 88% (7/8) of the trials assessing this outcome had high risk for allocation, and 38% (3/8) showed high risk for attrition bias for this outcome.<br/><sup>c</sup>Downgraded 2 levels for limitations in design and execution: 75% (3/4) of the trials assessing this outcome had high risk for allocation, and 50% (2/4) showed high risk for attrition bias, and 75% (3/4) had high risk for detection bias for this outcome.<br/><sup>d</sup>Dowgraded 2 levels due to high risk of bias and imprecision (small number of events).<br/><sup>e</sup>Downgraded 2 levels for limitations in design and execution: 75% (3/4) of the trials assessing this outcome had high risk for allocation, and 75% (3/4) showed high risk for detection bias for this outcome.<br/><sup>f</sup>Downgraded 2 levels for limitations in design and execution: 80% (4/5) of the trials assessing this outcome had high risk for allocation, and 40% (2/5) showed high risk for attrition bias, and 75% (3/4) had high risk for detection bias for this outcome. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013066-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013066-sec-0009"></div> <section id="CD013066-sec-0010"> <h3 class="title" id="CD013066-sec-0010">Description of the condition</h3> <p>Stroke is one of the leading causes of long‐lasting disability and mortality (<a href="./references#CD013066-bbs2-0085" title="MartynovMY , GusevEJ . Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of Experimental Pharmacology2015;7:17–28. [PMID: 27186142]">Martynov 2015</a>; <a href="./references#CD013066-bbs2-0123" title="YanLL , LiC , ChenJ , LuoR , BettgerJ , ZhuY , et al. Stroke. In: PrabhakaranD , AnandS , GazianoTA , MbanyaJC , WuY , NugentR , editors(s). Disease Control Priorities (openknowledge.worldbank.org/handle/10986/28875). 3rd edition. Vol. 5. Washington (DC): World Bank, 2017:157-76. [ISBN (electronic): 978-1-4648-0520-2]">Yan 2017</a>). The global burden of stroke has increased in the past two decades (<a href="./references#CD013066-bbs2-0057" title="HankeyGJ . Stroke. Lancet2017;389(10069):641-54. [PMID: 27637676]">Hankey 2017</a>). In 2015, ischemic heart disease and stroke were the two leading causes of premature mortality worldwide, and the leading causes of years of life lost (YLLs) in 119 countries and territories (<a href="./references#CD013066-bbs2-0117" title="WangH , NaghaviM , AllenC , BarberRM , BhuttaZA , CarterA , GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet2016;388:1459–544. [PMID: 27733281 ]">Wang 2016</a>). Finding a safe, inexpensive therapy to prevent and treat stroke is becoming an area of interest in international public health. </p> <p>Stroke is defined as an acute (sudden) episode characterized by clinical signs of focal or global disturbance of cerebral (brain) function caused by infarction (blockage in blood flow) or spontaneous hemorrhage (bleeding) in the relevant part of the brain, retina, or spinal cord, lasting more than 24 hours, or of any duration if imaging (computed tomography [CT]; or magnetic resonance imaging [MRI]) or autopsy show focal infarction or hemorrhage relevant to the symptoms. By comparison, a transient ischemic attack (TIA) is defined as a focal dysfunction of less than 24 hours' duration and with no imaging evidence of infarction (<a href="./references#CD013066-bbs2-0057" title="HankeyGJ . Stroke. Lancet2017;389(10069):641-54. [PMID: 27637676]">Hankey 2017</a>; <a href="./references#CD013066-bbs2-0095" title="PortegiesML , KoudstaalPJ , IkramMA . Cerebrovascular disease. In: AminoffMJ , BollerF , SwaaDF , editors(s). Handbook of Clinical Neurology. Vol. 138. Radarweg, Amsterdam, Netherlands: Elsevier, 2016:239-61. [ISBN: 978-0-12-802973-2] [PMID: 27637962]">Portegies 2016</a>). Stroke is classified into ischemic stroke (obstruction of cerebral blood), intracerebral hemorrhage (a focal collection of blood within the brain parenchyma or ventricular system that is not caused by trauma), and subarachnoid hemorrhage (bleeding into the subarachnoid space). Ischemic stroke is the most prevalent type and accounts for 75% to 85% of all strokes (<a href="./references#CD013066-bbs2-0034" title="CassellaCR , JagodaA . Ischemic stroke: advances in diagnosis and management. Emergency Medicine Clinics of North America2017;35(4):911-30. [PMID: 28987436]">Cassella 2017</a>; <a href="./references#CD013066-bbs2-0085" title="MartynovMY , GusevEJ . Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of Experimental Pharmacology2015;7:17–28. [PMID: 27186142]">Martynov 2015</a>). This Cochrane Review focused on acute ischemic stroke. </p> <p>Different strategies have been proposed for the recovery from, and treatment of, ischemic stroke. During the first few hours of onset of an ischemic stroke, blood flow can be restored through mechanical thrombus extraction (thrombectomy) or by intravenous thrombolysis with the administration of recombinant tissue plasminogen activators (rt‐PA) that break down blood clots. However, only 5% to 20% of people with acute ischemic stroke are treated with thrombolysis or thrombus extraction, or both (<a href="./references#CD013066-bbs2-0085" title="MartynovMY , GusevEJ . Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of Experimental Pharmacology2015;7:17–28. [PMID: 27186142]">Martynov 2015</a>; <a href="./references#CD013066-bbs2-0119" title="WardlawJM , MurrayV , BergeE , delZoppoJG . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD000213. [DOI: 10.1002/14651858.CD000213.pub3]">Wardlaw 2014</a>). </p> <p>Three parenchymal vascular states are seen in people with acute ischemic stroke, namely: the ischemic core; the zone of penumbra adjacent to it; and the region of benign oligemia adjacent to that (<a href="./references#CD013066-bbs2-0084" title="ManningNW , CampbellBC , OxleyTJ , ChapotR . Acute ischemic stroke: time, penumbra, and reperfusion. Stroke2014;45(2):640-4. [PMID: 24399376]">Manning 2014</a>). The ischemic penumbra region is defined as the "zone of nonfunctioning but still viable tissue that may recover its function if blood flow can be restored for example, by therapeutic intervention" (<a href="./references#CD013066-bbs2-0023" title="AstrupJ , SiesjoBK , SymonL . Thresholds in cerebral ischemia - the ischemic penumbra. Stroke1981;12(6):723-5. [PMID: 6272455]">Astrup 1981</a>; <a href="./references#CD013066-bbs2-0024" title="AstrupJ . Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy. Journal of Neurosurgery1982;56(4):482-97. [PMID: 6278105]">Astrup 1982</a>). The penumbra region represents that portion of the ischemic territory that is still potentially salvageable, and so it is the target of all acute therapies (<a href="./references#CD013066-bbs2-0064" title="HillisAE , BaronJC . Editorial: the ischemic penumbra: still the target for stroke therapies?Frontiers in Neurology2015;6:85. [PMID: 25954244]">Hillis 2015</a>; <a href="./references#CD013066-bbs2-0084" title="ManningNW , CampbellBC , OxleyTJ , ChapotR . Acute ischemic stroke: time, penumbra, and reperfusion. Stroke2014;45(2):640-4. [PMID: 24399376]">Manning 2014</a>; <a href="./references#CD013066-bbs2-0085" title="MartynovMY , GusevEJ . Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of Experimental Pharmacology2015;7:17–28. [PMID: 27186142]">Martynov 2015</a>). Therefore, the zone of penumbra must be protected; this protection is called neuroprotection. In this scenario, neuroprotection has been defined as "administering therapy as rapidly as possible following the onset of symptoms in an effort to minimize cerebral infarction while the ischemic brain is awaiting reperfusion" (<a href="./references#CD013066-bbs2-0091" title="PatelRA , McMullenPW . Neuroprotection in the treatment of acute ischemic stroke. Progress in Cardiovascular Diseases2017;59(6):542-8. [PMID: 28465001]">Patel 2017</a>). There are pharmacological and non‐pharmacological forms of neuroprotection (<a href="./references#CD013066-bbs2-0091" title="PatelRA , McMullenPW . Neuroprotection in the treatment of acute ischemic stroke. Progress in Cardiovascular Diseases2017;59(6):542-8. [PMID: 28465001]">Patel 2017</a>; <a href="./references#CD013066-bbs2-0118" title="WangY , LiuH , LinY , LiuG , ChuH , ZhaoP , et al. Network-based approach to identify potential targets and drugs that promote neuroprotection and neurorepair in acute ischemic stroke. Scientific Reports2017;7:40137. [PMID: 28054643]">Wang 2017</a>), and this Cochrane Review focused on one type of pharmacological neuroprotector: citicoline. </p> <p>Several studies have suggested that citicoline is effective for treating central nervous system disorders (CNS), including acute and chronic cerebral ischemia, intracerebral hemorrhage, global cerebral hypoxia, and neurodegenerative diseases (<a href="./references#CD013066-bbs2-0085" title="MartynovMY , GusevEJ . Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of Experimental Pharmacology2015;7:17–28. [PMID: 27186142]">Martynov 2015</a>). These studies claim that citicoline treatment reduces size of infarct (region of dead tissue), decreases free fatty acid concentration, decreases neurologic deficits, restores animal learning performance, reduces glutamate‐mediated injury, preserves phosphatidylcholine levels, and improves neuronal survival (<a href="./references#CD013066-bbs2-0038" title="ClarkWM . Efficacy of citicoline as an acute stroke treatment. Expert Opinion on Pharmacotherapy2009;10(5):839-46. [PMID: 19351232 ]">Clark 2009</a>). </p> </section> <section id="CD013066-sec-0011"> <h3 class="title" id="CD013066-sec-0011">Description of the intervention</h3> <p>Citicoline is the generic name for cytidine 5'‐diphosphocholine (CDP‐choline). Citicoline is the combination of two molecules: cytidine and choline. These molecules cross the blood‐brain barrier separately; after reaching the brain cells they combine to generate CDP‐choline (<a href="./references#CD013066-bbs2-0085" title="MartynovMY , GusevEJ . Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of Experimental Pharmacology2015;7:17–28. [PMID: 27186142]">Martynov 2015</a>). Thus, it is a natural endogenous compound and a precursor for the synthesis of phosphatidylcholine, one of the components of cell membranes. During cerebral ischemia, phosphatidylcholine is broken down into free fatty acids and free radicals that increase the likelihood of ischemic injury (<a href="./references#CD013066-bbs2-0038" title="ClarkWM . Efficacy of citicoline as an acute stroke treatment. Expert Opinion on Pharmacotherapy2009;10(5):839-46. [PMID: 19351232 ]">Clark 2009</a>). </p> <p>Citicoline is synthesized in oral and enteral formulations for clinical practice. Citicoline is a water‐soluble compound, and pharmacokinetic studies on healthy adults have shown an optimal absorption of both oral and intravenous doses. Once absorbed, citicoline is converted to choline and cytidine, which circulate in the body, enter systemic circulation and cross the blood–brain barrier for resynthesis into citicoline in the brain (<a href="./references#CD013066-bbs2-0038" title="ClarkWM . Efficacy of citicoline as an acute stroke treatment. Expert Opinion on Pharmacotherapy2009;10(5):839-46. [PMID: 19351232 ]">Clark 2009</a>). Citicoline has been administered intravenously at doses ranging between 500 mg and 2000 mg respectively in randomized controlled trials (RCTs) (<a href="./references#CD013066-bbs2-0026" title="Ávarez-SabínJ , RománGC . The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sciences2013;3(3):1395-414. [PMID: 24961534]">Avarez‐Sabín 2013</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>). </p> </section> <section id="CD013066-sec-0012"> <h3 class="title" id="CD013066-sec-0012">How the intervention might work</h3> <p>The cytidine‐5'‐diphosphocholine (CDP‐choline or citicoline) pathway begins with the uptake of exogenous choline into the cell, followed by different enzymatic reactions that lead to the synthesis of phosphatidylcholine. The hypothesized mechanism of action assumes that citicoline undergoes hydrolysis and dephosphorylation to yield cytidine and choline products. These breakdown products then enter the brain separately and act as substrates for the resynthesis of CDP‐choline. This mechanism is believed to slow down phospholipid breakdown and accelerate phospholipid resynthesis, which are necessary for membrane repair (<a href="./references#CD013066-bbs2-0056" title="GriebP . Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs2014;28(3):185-93. [PMID: 24504829 ]">Grieb 2014</a>). Citicoline is a free radical scavenger that reduces the availability of free radicals after acute ischemic episodes (<a href="./references#CD013066-bbs2-0096" title="RajahGB , DingY . Experimental neuroprotection in ischemic stroke: a concise review. Neurosurgical Focus2017;42(4):E2. [PMID: 28366067]">Rajah 2017</a>), and so may slow the damage. It may facilitate recovery by activating neurogenesis, synaptogenesis, and angiogenesis (creation of brain cells, gaps between them, and blood supply), and enhances neurotransmitter metabolism. In an animal model, administration of citicoline showed an up‐regulation of synaptophysin in the penumbra region that could indicate an increase of synaptic (brain) activity (<a href="./references#CD013066-bbs2-0085" title="MartynovMY , GusevEJ . Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of Experimental Pharmacology2015;7:17–28. [PMID: 27186142]">Martynov 2015</a>). </p> <p>The administration of citicoline increases brain choline, and accelerates the synthesis of phosphatidylcholine, decreases levels of free fatty acids, and reduces the generation of free radicals. Overall, the administration of citicoline may protect cell membranes by reducing phosphatidylcholine breakdown (<a href="./references#CD013066-bbs2-0085" title="MartynovMY , GusevEJ . Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of Experimental Pharmacology2015;7:17–28. [PMID: 27186142]">Martynov 2015</a>). Recent research suggests that citicoline may enhance endogenous brain plasticity and repair even when it is administered several hours after the ischemic event (<a href="./references#CD013066-bbs2-0038" title="ClarkWM . Efficacy of citicoline as an acute stroke treatment. Expert Opinion on Pharmacotherapy2009;10(5):839-46. [PMID: 19351232 ]">Clark 2009</a>; <a href="./references#CD013066-bbs2-0090" title="OvergaardK . The effects of citicoline on acute ischemic stroke: a review. Journal of Stroke and Cerebrovascular Diseases2014;23(7):1764-9. [PMID: 24739589]">Overgaard 2014</a>). An animal study reported significantly improved motor and functional recovery in the citicoline‐treated group at the end of a 28‐day intervention period, when citicoline was given 24 hours after middle cerebral artery stroke, and taken for 28 days (<a href="./references#CD013066-bbs2-0038" title="ClarkWM . Efficacy of citicoline as an acute stroke treatment. Expert Opinion on Pharmacotherapy2009;10(5):839-46. [PMID: 19351232 ]">Clark 2009</a>). </p> </section> <section id="CD013066-sec-0013"> <h3 class="title" id="CD013066-sec-0013">Why it is important to do this review</h3> <p>This Cochrane Review is important because controversy exists regarding the clinical effectiveness of citicoline for treating people with acute stroke. Some randomized placebo, or head‐to‐head, controlled clinical trials and meta‐analyses suggest limited or no clinical benefits (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0013" title="GoelD . ECCT-HIS. Edaravone-Citicoline comparative trial in head injury and stroke. Available at www.strokecenter.org/trials/clinicalstudies/edaravone-citicoline-comparative-trial-in-head-injury-and-stroke. MittalM , GoelD , BansalKK , PuriP . Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). Journal of the Association of Physicians of India2012;60(11):36-8. [PMID: 23767201]">ECCS‐ AIS 2012</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0104" title="SecadesJJ , Alvarez-SabinJ , CastilloJ , Diez-TejedorE , Martinez-VilaE , RiosJ , et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. Journal of Stroke and Cerebrovascular Diseases2016;25(8):1984-96. [PMID: 27234918]">Secades 2016</a>; <a href="./references#CD013066-bbs2-0106" title="ShiPY , ZhouXC , YinXX , XuLL , ZhangXM , BaiHY . Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology. Medical Sciences2016;36(2):270-7. [MEDLINE: 27072975 ]">Shi 2016</a>), while other randomized, placebo‐controlled clinical trials report beneficial effects (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). Furthermore, <a href="./references#CD013066-bbs2-0041" title="DávalosA , CastilloJ , Alvarez-SabinJ , SecadesJJ , MercadalJ , LopezS , et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke2002;33(12):2850-7. [PMID: 12468781]">Dávalos 2002</a>, <a href="./references#CD013066-bbs2-0104" title="SecadesJJ , Alvarez-SabinJ , CastilloJ , Diez-TejedorE , Martinez-VilaE , RiosJ , et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. Journal of Stroke and Cerebrovascular Diseases2016;25(8):1984-96. [PMID: 27234918]">Secades 2016</a>, and <a href="./references#CD013066-bbs2-0106" title="ShiPY , ZhouXC , YinXX , XuLL , ZhangXM , BaiHY . Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology. Medical Sciences2016;36(2):270-7. [MEDLINE: 27072975 ]">Shi 2016</a> have several methodological limitations such as lack of reporting summary of finding tables, use of odds ratio instead of risk ratio, and use of cumulative meta‐analysis (<a href="./references#CD013066-bbs2-0110" title="SterneJA , BradburnMJ , EggerM . Meta-analysis in StataTM . In: EggerM , SmithDS , and AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition. London (UK): BMJ Books, 2001:347-69. [978-0-7279-1488-0]">Sterne 2001</a>), instead of Trial Sequential Analysis (TSA) (<a href="./references#CD013066-bbs2-0122" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [PMID: 28264661]">Wetterslev 2017</a>). Regarding odds ratio, there are several publications opposed to the use of odds ratio in conducting systematic reviews (<a href="./references#CD013066-bbs2-0022" title="AltmanDG , DeeksJJ , SackettDL . Odds ratios should be avoided when events are common. BMJ1998;317(7168):1318. [PMID: 9804732]">Altman 1998</a>; <a href="./references#CD013066-bbs2-0027" title="BarnesDE , BeroLA . Why review articles on the health effects of passive smoking reach different conclusions. JAMA1998;279(19):1566-70. [PMID: 9605902]">Barnes 1998</a>; <a href="./references#CD013066-bbs2-0030" title="BlandJM , AltmanDG . Statistics notes. The odds ratio. BMJ2000;320(7247):1468. [PMID: 10827061]">Bland 2000</a>; <a href="./references#CD013066-bbs2-0042" title="DaviesHT , CrombieIK , TavakoliM . When can odds ratios mislead?BMJ1998;316(7136):989-91. [PMID: 9550961]">Davies 1998</a>; <a href="./references#CD013066-bbs2-0063" title="HigginsJPT , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019:143-176.">Higgins 2019</a>; <a href="./references#CD013066-bbs2-0099" title="SackettDL , DeeksJ , AltmanDG . Down with odds ratios!Evidence-based Medicine1996;1:164-6.">Sackett 1996</a>). In addition, drug companies have funded many trials (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>), and it is necessary to assess the effectiveness of the drug independently (<a href="./references#CD013066-bbs2-0082" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a>). Argentina, Austria, Chile, Indonesia, Mexico, Portugal, Thailand, and Venezuela prescribe citicoline (<a href="./references#CD013066-bbs2-0037" title="ChenX , WangK . The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015. Acta Pharmaceutica Sinica B2016;6(6):522–30. [PMID: 27818918]">Chen 2016</a>). Since 17 April 2009, citicoline has been banned in the USA and Canada (<a href="./references#CD013066-bbs2-0037" title="ChenX , WangK . The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015. Acta Pharmaceutica Sinica B2016;6(6):522–30. [PMID: 27818918]">Chen 2016</a>; <a href="./references#CD013066-bbs2-0048" title="US Food and Drug Administration. www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-nootropics-llc-565425-020520192019.">FDA 2019</a>). Conducting a systematic review according to Cochrane methodology is fundamental to identify the clinical benefits and harms of citicoline compared with placebo or any other control for treating people with acute ischemic stroke. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013066-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013066-sec-0014"></div> <p>To assess the clinical benefits and harms of citicoline compared with placebo, any other drug or usual care for treating people with acute ischemic stroke. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013066-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013066-sec-0015"></div> <section id="CD013066-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013066-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) irrespective of publication status. We did not apply any limitation by language, country, or duration of follow‐up. We only included parallel‐design trials. </p> </section> <section id="CD013066-sec-0018"> <h4 class="title">Types of participants</h4> <p>People (children or adults) with acute ischemic stroke, irrespective of etiology. We used clinical diagnosis with imaging as an eligibility criterion. </p> </section> <section id="CD013066-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials that compared citicoline with placebo, usual care, or other interventions.</p> <p>Citicoline administered at any dose, by any route, and for any duration of treatment, versus no intervention, placebo, or other interventions. Since acute ischemic stroke requires a variety of medical treatments (that is, primary interventions), we considered citicoline as a supplementary intervention. Thus, for the purpose of this review, eligible RCTs were those that compared the same primary interventions with and without citicoline supplementation. </p> </section> <section id="CD013066-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD013066-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013066-list-0001"> <li> <p>All‐cause mortality (at 90 days).</p> </li> <li> <p>Degree of disability or dependence in daily activities according to the modified Rankin scale (at 90 days) (<a href="./references#CD013066-bbs2-0058" title="HarrisonJK , McArthurKS , QuinnTJ . Assessment scales in stroke: clinimetric and clinical considerations. Clinical Interventions in Aging2013;8:201-11. [PMID: 23440256]">Harrison 2013</a>; <a href="./references#CD013066-bbs2-0087" title="McArthurKS . Improving efficiency in stroke trials: an exploration of methods to improve the use of the modified Rankin Scale in acute stroke trials. theses.gla.ac.uk/53502014:1-261.">McArthur 2014</a>; <a href="./references#CD013066-bbs2-0116" title="vanSwietenJC , KoudstaalPJ , VisserMC , SchoutenHJ , vanGijnJ . Interobserver agreement for the assessment of handicap in stroke patients. Stroke1988;19(5):604-7. [PMID: 3363593]">van Swieten 1988</a>). See <a href="./appendices#CD013066-sec-0110">Appendix 1</a>. </p> </li> </ul> </p> </section> <section id="CD013066-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013066-list-0002"> <li> <p>Adverse events during the first 30 days, assessed according to recommendations from <a href="./references#CD013066-bbs2-0080" title="LineberryN , BerlinJA , MansiB , GlasserS , BerkwitsM , KlemC , et al. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ2016;355:i5078. [PMID: 27697753]">Lineberry 2016</a>. </p> </li> <li> <p>Functional recovery: assessed with the Barthel Index (at 90 days) (<a href="./references#CD013066-bbs2-0058" title="HarrisonJK , McArthurKS , QuinnTJ . Assessment scales in stroke: clinimetric and clinical considerations. Clinical Interventions in Aging2013;8:201-11. [PMID: 23440256]">Harrison 2013</a>; <a href="./references#CD013066-bbs2-0083" title="MahoneyFI , BarthelDW . Functional evaluation: the Barthel index. Maryland State Medical Journal1965;14:61-5. [PMID: 14258950]">Mahoney 1965</a>). See <a href="./appendices#CD013066-sec-0111">Appendix 2</a> for details. </p> </li> <li> <p>Neurological function assessed with the National Institutes of Health Stroke Scale (NIHSS) (<a href="./references#CD013066-bbs2-0058" title="HarrisonJK , McArthurKS , QuinnTJ . Assessment scales in stroke: clinimetric and clinical considerations. Clinical Interventions in Aging2013;8:201-11. [PMID: 23440256]">Harrison 2013</a>). We assessed this at the first 24 hours (acute phase), at 72 hours, and at discharge. See <a href="./appendices#CD013066-sec-0112">Appendix 3</a> for details. </p> </li> <li> <p>Quality of life (at 90 days): assessed using the 36‐item Short Form Survey (SF‐36), EuroQol, the Stroke Specific Quality of Life scale (SS‐QoL) (<a href="./references#CD013066-bbs2-0058" title="HarrisonJK , McArthurKS , QuinnTJ . Assessment scales in stroke: clinimetric and clinical considerations. Clinical Interventions in Aging2013;8:201-11. [PMID: 23440256]">Harrison 2013</a>). </p> </li> </ul> </p> <p>The timing of outcome measures indicates the approximate target for the review. It is based on the conventional timing used in the assessment of these outcomes. </p> </section> </section> </section> <section id="CD013066-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>See the methods for the Cochrane Stroke Group <a href="http://www.dcn.ed.ac.uk/csrg/entity/searchmethods.pdf" target="_blank">Specialised register</a>. We searched for trials in all languages and arranged for translation of relevant articles where necessary. </p> <section id="CD013066-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched in the Cochrane Stroke Group Trials Register and the following electronic databases. </p> <p> <ul id="CD013066-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 1) in the Cochrane Library (searched 29 January 2020) (<a href="./appendices#CD013066-sec-0113">Appendix 4</a>) </p> </li> <li> <p>MEDLINE Ovid (from 1948 to 29 January 2020) (<a href="./appendices#CD013066-sec-0114">Appendix 5</a>) </p> </li> <li> <p>Embase Ovid (from 1974 to 29 January 2020) (<a href="./appendices#CD013066-sec-0115">Appendix 6</a>) </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database; 1982 to 29 January 2020) <a href="./appendices#CD013066-sec-0116">Appendix 7</a> </p> </li> </ul> </p> <p>With the assistance of the Cochrane Stroke Group's Information Specialist, we designed the search strategy in MEDLINE and adapted it to all other databases (<a href="./appendices#CD013066-sec-0114">Appendix 5</a>). We combined all search strategies deployed with subject strategy adaptations of the Highly Sensitive Search Strategy designed by Cochrane for identifying randomized controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6: <a href="./references#CD013066-bbs2-0079" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). </p> </section> <section id="CD013066-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also searched the following ongoing trials registries.</p> <p> <ul id="CD013066-list-0004"> <li> <p>US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.ClinicalTrials.gov</a>) (<a href="./appendices#CD013066-sec-0117">Appendix 8</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en" target="_blank">www.who.int/ictrp/en</a>) (<a href="./appendices#CD013066-sec-0118">Appendix 9</a>) </p> </li> <li> <p>Stroke Trials Registry (<a href="http://www.strokecenter.org/trials/" target="_blank">www.strokecenter.org/trials</a>) </p> </li> </ul> </p> <p>In order to identify unpublished information submitted for the marketing approval of citicoline, we also searched the following sites. </p> <p> <ul id="CD013066-list-0005"> <li> <p>Food and Drug Administration (<a href="http://www.fda.gov" target="_blank">www.fda.gov</a>) (<a href="./appendices#CD013066-sec-0119">Appendix 10</a>); </p> </li> <li> <p>European Medicines Agency (<a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema</a>) (<a href="./appendices#CD013066-sec-0120">Appendix 11</a>). </p> </li> </ul> </p> <p>We screened the reference lists of relevant studies and use Cited Reference Search within Web of Science to identify further studies for potential inclusion in the review, and we contacted trialists and companies for further information. </p> </section> </section> <section id="CD013066-sec-0026"> <h3 class="title" id="CD013066-sec-0026">Data collection and analysis</h3> <p>We conducted data collection and analysis of data according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013066-bbs2-0060" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>; <a href="./references#CD013066-bbs2-0061" title="HigginsJP , DeeksJJ , editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). </p> <section id="CD013066-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AMC, CV) independently screened titles and abstracts of the references obtained as a result of our searching activities, and excluded obviously irrelevant reports. We retrieved the full‐text articles for the remaining references and, independently, two or more review authors (AMC, CV, IS) screened the full‐text articles and identified studies for inclusion. They also identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreements through discussion or, if required, we consulted a third review author (JMF). We collated multiple reports of the same study so that each study, not each reference, was the unit of interest in the review. We recorded the selection process and completed a PRISMA flow diagram. </p> </section> <section id="CD013066-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AMC, CV) independently extracted data from included studies. We developed an Excel spreadsheet based on the 'Data extraction template for included studies' from the <a href="http://cccrg.cochrane.org/author-resources" target="_blank">Consumers and Communication Group resources for authors</a>. We planned to describe the details of the intervention following recommendations from <a href="./references#CD013066-bbs2-0065" title="HoffmannTC , GlasziouPP , BoutronI , MilneR , PereraR , MoherD , et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ2014;348:g1687. [PMID: 24609605]">Hoffmann 2014</a> and <a href="./references#CD013066-bbs2-0066" title="HoffmannTC , OxmanAD , IoannidisJP , MoherD , LassersonTJ , ToveyDI , et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. BMJ2017;357:j2998. [PMID: 28729459]">Hoffmann 2017</a>. </p> </section> <section id="CD013066-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AMC, CV) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013066-bbs2-0062" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org.">Higgins 2011c</a>). We resolved any disagreements by discussion or by involving another review author (JMF, XB). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD013066-list-0006"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ul> </p> <p>We graded the risk of bias for each domain as high, low, or unclear and provide information from the study report together with a justification of our judgment in the 'Risk of bias' tables. </p> <p>We included company funding, bias in the presentation of the data, design bias, measurements and confounding biases under 'Other bias'. See <a href="./references#CD013066-bbs2-0094" title="PortaM . A Dictionary of Epidemiology. 6th edition. New York: Oxford University Press, 2014. [ISBN 978-0-19-997672-0]">Porta 2014</a> for definitions of the examples of biases. </p> <p>See <a href="./appendices#CD013066-sec-0121">Appendix 12</a> for details of domains. </p> </section> <section id="CD013066-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes in this review, such as all‐cause mortality and adverse events, we calculated the risk ratio (RR) with 95% confidence intervals (CIs). </p> <p>For future updates we will follow this approach: for continuous outcomes, such as functional outcome, degree of disability or dependence in daily activities, and neurological, behavioral and cognitive function, we plan to calculate the mean difference (MD) with 95% CI. If ordinal data are reported, we will use a proportional odds model as a measure of treatment effect with Stata statistical software (<a href="./references#CD013066-bbs2-0109" title="StataCorpLLC . Stata 14. www.stata.com.">STATA</a>) (<a href="./references#CD013066-bbs2-0029" title="BathPM , LeesKR , SchellingerPD , AltmanH , BlandM , HoggC , et al. Statistical analysis of the primary outcome in acute stroke trials. Stroke2012;43(4):1171-8. [PMID: 22426314]">Bath 2012</a>: <a href="./references#CD013066-bbs2-0043" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017.The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>; <a href="./references#CD013066-bbs2-0103" title="ScottSC , GoldbergMS , MayoNE . Statistical assessment of ordinal outcomes in comparative studies. Journal of Clinical Epidemiology1997;50(1):45-55. [PMID: 9048689]">Scott 1997</a>). If different scales are used for measuring the same outcome, for example quality of life, we plan to use the standardized mean difference (SMD) with 95% CI. We will also estimate ratio of means (RoM) with 95% CI from mean difference (<a href="./references#CD013066-bbs2-0049" title="FriedrichJO , AdhikariNK , BeyeneJ . Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. Journal of Clinical Epidemiology2011;64(5):556-64. [PMID: 21447428]">Friedrich 2011</a>). Due to practitioners' understanding and preferring dichotomous presentations of continuous outcomes, which they perceive to be the most useful (<a href="./references#CD013066-bbs2-0075" title="JohnstonBC , Alonso-CoelloP , FriedrichJO , MustafaRA , TikkinenKA , NeumannI , et al. Do clinicians understand the size of treatment effects? A randomized survey across 8 countries. Canadian Medical Association Journal2016;188(1):25-32. [PMID: 26504102]">Johnston 2016</a>), we will estimate odds ratios (OR) with 95% CI and the number needed to treat for an additional beneficial outcome (NNTB) from SMD with Furukawa's method (<a href="./references#CD013066-bbs2-0050" title="FurukawaTA . From effect size into number needed to treat. Lancet1999;353(9165):1680. [PMID: 10335798]">Furukawa 1999</a>; <a href="./references#CD013066-bbs2-0051" title="FurukawaTA , LeuchtS . How to obtain NNT from Cohen's d: comparison of two methods. PLoS One2011;6(4):e19070. [PMID: 21556361]">Furukawa 2011</a>). </p> <p>As recommended in section 9.2.3.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013066-bbs2-0060" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>), if necessary we will multiply the mean values from one set of studies by −1 to ensure that all the scales point in the same direction (<a href="./references#CD013066-bbs2-0043" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017.The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> <p>If statistical information is missing (such as standard deviations), we will try to extract them from other relevant information in the paper, such as P values and CIs. </p> <p>We will calculate the NNTB if the RR was significant (P value &lt; 0.05). NNTB is a measure of assessment of clinical useful of the consequences of treatment (<a href="./references#CD013066-bbs2-0077" title="LaupacisA , SackettDL , RobertsRS . An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine1988;318(26):1728-33. [PMID: 3374545]">Laupacis 1988</a>). We will estimate NNTB with <a href="http://graphpad.com/quickcalcs/NNT2/" target="_blank">GraphPad software</a> and with the <a href="http://www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp" target="_blank">Cochrane Stroke Group NNT calculator</a>. If ordinal data are reported, we will estimate NNTB according to <a href="./references#CD013066-bbs2-0028" title="BathP , HoggC , TracyM , PocockS . Calculation of numbers-needed-to-treat in parallel group trials assessing ordinal outcomes: case examples from acute stroke and stroke prevention. International Journal of Stroke2011;6(6):472-9. [PMID: 21645271]">Bath 2011</a>. </p> </section> <section id="CD013066-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was participants. We excluded cluster RCTs.</p> <p>As recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> we conducted the following plan to assess the outcomes with multiple observations. </p> <p> <ul id="CD013066-list-0007"> <li> <p>For primary outcomes (all‐cause mortality and degree of disability or dependence in daily activities according to the modified Rankin scale) and secondary outcomes (adverse events, functional recovery and quality of life), we selected a single time point and analyzed only data at this time for trials in which it will be presented. </p> </li> <li> <p>Neurological function assessed with the National Institutes of Health Stroke Scale (secondary outcome): we planned to define different periods of follow‐up (short‐term, medium‐term, and long‐term follow‐up) (<a href="./references#CD013066-bbs2-0043" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017.The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>), and perform separate analyses. </p> </li> </ul> </p> </section> <section id="CD013066-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We assessed the percentage of dropouts for each intervention group for each included trial, and evaluated whether an intention‐to‐treat (ITT) analysis was performed or could have been performed from the available published information. We contacted study authors to resolve any questions arising from this issue. </p> <p>In order to undertake an ITT analysis, we sought data from the trial authors about the number of participants in treatment groups, irrespective of their compliance and whether or not they were later thought to be ineligible, otherwise excluded from treatment, or lost to follow‐up. If this information was not forthcoming, we performed a 'per protocol' analysis of those who completed the study, being aware that it may be biased. </p> <p>We included participants with incomplete or missing data in sensitivity analyses by imputing them according to the following scenarios (<a href="./references#CD013066-bbs2-0067" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed)1999;319(7211):670-4. [PMID: 10480822]">Hollis 1999</a>). </p> <p> <ul id="CD013066-list-0008"> <li> <p>Extreme case analysis favoring the experimental intervention ('best‐worse' case scenario): none of the drop‐outs/participants lost from the experimental arm, but all of the drop‐outs/participants lost from the control arm experienced the outcome, including all randomized participants in the denominator. </p> </li> <li> <p>Extreme case analysis favoring the control ('worst‐best' case scenario): all drop‐outs/participants lost from the experimental arm, but none from the control arm experienced the outcome, including all randomized participants in the denominator. </p> </li> <li> <p>Gamble‐Hollis analysis, which takes account of the uncertainty and generates uncertainty intervals for a trial incorporating both sampling error and the potential impact of missing data (<a href="./references#CD013066-bbs2-0052" title="GambleC , HollisS . Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology2005;58(6):579-88. [PMID: 15878471]">Gamble 2005</a>). This method increases the uncertainty of the trials using the results from the best‐case and worst‐case analyses (<a href="./references#CD013066-bbs2-0035" title="ChaimaniA , MavridisD , SalantiG . A hands-on practical tutorial on performing meta-analysis with Stata. Evidence-based Mental Health2014;17(4):111-6. [PMID: 25288685]">Chaimani 2014</a>). </p> </li> </ul> </p> </section> <section id="CD013066-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across trials that is due to heterogeneity rather than sampling error (<a href="./references#CD013066-bbs2-0059" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [PMID: 12958120]">Higgins 2003</a>). We had set an I² threshold greater than 60% to consider the presence of statistical heterogeneity (<a href="./references#CD013066-bbs2-0043" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017.The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> </section> <section id="CD013066-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not identify 10 or more RCTs to conduct the assessment of reporting biases for any outcome. For the future update, therefore, we will use the contour‐enhanced funnel plot to differentiate asymmetry that is due to publication bias from that due to other factors (<a href="./references#CD013066-bbs2-0092" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology2008;61(10):991-6. [PMID: 18538991]">Peters 2008</a>). We will assess likelihood of publication bias with Harbord's and Peters' tests (<a href="./references#CD013066-bbs2-0111" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002. [PMID: 21784880]">Sterne 2011</a>). We will use Stata statistical software to produce conventional and contour funnel plots (<a href="./references#CD013066-bbs2-0109" title="StataCorpLLC . Stata 14. www.stata.com.">STATA</a>). </p> </section> <section id="CD013066-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analyses with 95% CI using either a fixed‐effect or random‐effects model. For future updates, in case of statistical heterogeneity (I² &gt; 60%), we will report data using the random‐effects model and prediction interval (<a href="./references#CD013066-bbs2-0043" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017.The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>; <a href="./references#CD013066-bbs2-0070" title="IntHoutJ , IoannidisJP , RoversMM , GoemanJJ . Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open2016;6(7):e010247. [PMID: 27406637]">IntHout 2016</a>; <a href="./references#CD013066-bbs2-0098" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549. [PMID: 21310794]">Riley 2011</a>). We conducted meta‐analysis with Review Manager 5 (<a href="./references#CD013066-bbs2-0097" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <section id="CD013066-sec-0036"> <h5 class="title">Trial sequential analysis (TSA)</h5> <p>We applied trial sequential analysis (TSA), as cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD013066-bbs2-0031" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial Sequential Analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61(8):763-9. [PMID: 18411040]">Brok 2008</a>; <a href="./references#CD013066-bbs2-0032" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analyses may be inconclusive: Trial Sequential Analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98. [PMID: 18824466]">Brok 2009</a>; <a href="./references#CD013066-bbs2-0068" title="ImbergerG , GluudC , BoylanJ , WetterslevJ . Systematic reviews of anesthesiologic interventions reported as statistically significant: problems with power, precision, and type 1 error protection. Anesthesia and Analgesia2015;121(6):1611-22. [PMID: 26579662]">Imberger 2015</a>; <a href="./references#CD013066-bbs2-0069" title="ImbergerG , ThorlundK , GluudC , WetterslevJ . False-positive findings in Cochrane meta-analyses with and without application of Trial Sequential Analysis: an empirical review. BMJ Open2016;6(8):e011890. [PMID: 27519923]">Imberger 2016</a>; <a href="./references#CD013066-bbs2-0112" title="ThorlundK , AnemaA , MillsE . Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology2010;2:57-66. [PMID: 20865104]">Thorlund 2010</a>; <a href="./references#CD013066-bbs2-0120" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [PMID: 18083463]">Wetterslev 2008</a>; <a href="./references#CD013066-bbs2-0121" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86. [PMID: 20042080]">Wetterslev 2009</a>; <a href="./references#CD013066-bbs2-0122" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [PMID: 28264661]">Wetterslev 2017</a>). To minimize random errors, we calculated the required information size (i.e. the number of participants needed in a meta‐analysis to detect or reject a certain plausible intervention effect) (<a href="./references#CD013066-bbs2-0120" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [PMID: 18083463]">Wetterslev 2008</a>; <a href="./references#CD013066-bbs2-0122" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [PMID: 28264661]">Wetterslev 2017</a>). The required information size calculation also accounted for the heterogeneity or diversity present in the meta‐analysis (<a href="./references#CD013066-bbs2-0120" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [PMID: 18083463]">Wetterslev 2008</a>; <a href="./references#CD013066-bbs2-0121" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86. [PMID: 20042080]">Wetterslev 2009</a>; <a href="./references#CD013066-bbs2-0122" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [PMID: 28264661]">Wetterslev 2017</a>). We used the event proportion in the control group; assumption of a plausible RR reduction of 20% or the RR reduction observed in the included trials with low risk of bias; a risk of type I error of 5%; a risk of type II error of 10%; and the empirical diversity of the meta‐analysis for estimating the diversity‐adjusted required information size (<a href="./references#CD013066-bbs2-0121" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86. [PMID: 20042080]">Wetterslev 2009</a>; <a href="./references#CD013066-bbs2-0122" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [PMID: 28264661]">Wetterslev 2017</a>). We added the trials according to the year of publication. On the basis of the required information size, we constructed trial sequential monitoring boundaries (<a href="./references#CD013066-bbs2-0076" title="LanGK , DeMetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70(3):659-63. [DOI: 10.1093/biomet/70.3.659]">Lan 1983</a>; <a href="./references#CD013066-bbs2-0113" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 6 March 2017).">Thorlund 2011a</a>; <a href="./references#CD013066-bbs2-0120" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [PMID: 18083463]">Wetterslev 2008</a>). These boundaries determined the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the required information size. If the trial sequential monitoring boundary for benefit or harm is crossed before the required information size is reached, further trials may turn out to be superfluous. On the other hand, if the boundary is not surpassed, it is probably necessary to continue conducting trials in order to detect or reject a certain intervention effect. This can be determined by assessing whether the cumulative Z‐curve crosses the trial sequential boundaries for futility. If futility boundaries are crossed, then further trials may be unnecessary (<a href="./references#CD013066-bbs2-0040" title="Copenhagen Trial Unit. TSA - Trial Sequential Analysis. ctu.dk/tsa/ (accessed 25 May 2017).">CTU 2011</a>). We conducted TSA using software from the Copenhagen Trial Unit (<a href="./references#CD013066-bbs2-0040" title="Copenhagen Trial Unit. TSA - Trial Sequential Analysis. ctu.dk/tsa/ (accessed 25 May 2017).">CTU 2011</a>; <a href="./references#CD013066-bbs2-0113" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 6 March 2017).">Thorlund 2011a</a>). We did only for the primary outcomes: all‐cause mortality and degree of disability or dependence in daily activities according to the modified Rankin scale. </p> </section> </section> <section id="CD013066-sec-0037"> <h4 class="title">GRADE and 'Summary of findings' table</h4> <p>We developed a 'Summary of findings' table with the following outcomes: all‐cause mortality; degree of disability or dependence in daily activities on the modified Rankin scale; adverse events; functional recovery (Barthel Index); neurological function (National Institutes of Health Stroke Scale: NIHSS); and quality of life (<a href="./full#CD013066-tbl-0001">summary of findings Table 1</a>). We assessed the quality of the evidence for each outcome according to GRADE domains (study limitations, consistency of effect, imprecision, indirectness and publication bias) (<a href="./references#CD013066-bbs2-0025" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. [PMID: 15205295]">Atkins 2004</a>). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013066-bbs2-0101" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011a</a>), and GRADEpro GDT software (<a href="./references#CD013066-bbs2-0055" title="GRADEpro GDT. Version accessed 29 May 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). We justified all decisions to downgrade the quality of the evidence using footnotes, and we made comments to aid the reader's understanding of the review where necessary. We calculated the assumed control group risks using the median control group risk (<a href="./references#CD013066-bbs2-0102" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al In: Higgins JP, GreenS , editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011) The Cochrane Collaboration, 2011. Chapter 11: Interpreting results and drawing conclusions. Available from handbook.cochrane.org.">Schünemann 2011b</a>). </p> </section> <section id="CD013066-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted the following subgroup analysis for primary outcomes if more than five trials were included. </p> <p> <ul id="CD013066-list-0009"> <li> <p>Trials supported by pharmaceutical companies versus trials without support by pharmaceutical companies. </p> </li> <li> <p>Trials with low risk of bias versus trials with high risk of bias.</p> </li> <li> <p>Trials with small sample size (≤ 200 participants) versus trials with large sample size (&gt; 200 participants). </p> </li> </ul> </p> <p>Due to lack of data, we were not able to conduct subgroup analysis with:</p> <p> <ul id="CD013066-list-0010"> <li> <p>participants with diabetes mellitus versus participants without diabetes mellitus;</p> </li> <li> <p>participants with high blood pressure versus participants without high blood pressure.</p> </li> </ul> </p> </section> <section id="CD013066-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis for primary outcomes with Stata statistical software (<a href="./references#CD013066-bbs2-0109" title="StataCorpLLC . Stata 14. www.stata.com.">STATA</a>), in order to explore the influence of particular factors on the intervention effect size: 'best‐worst case' scenario versus 'worst‐best case' scenario and Gamble‐Hollis analysis (<a href="./references#CD013066-bbs2-0052" title="GambleC , HollisS . Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology2005;58(6):579-88. [PMID: 15878471]">Gamble 2005</a>). </p> </section> <section id="CD013066-sec-0040"> <h4 class="title">Bayes factors</h4> <p>We estimated the threshold for clinical relevance for primary outcomes through use of Bayes factors (<a href="./references#CD013066-bbs2-0074" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). The Bayes factor is a likelihood ratio that indicates the relative strength of evidence for two theories (<a href="./references#CD013066-bbs2-0046" title="DienesZ . Using Bayes to get the most out of non-significant results. Frontiers in Psychology2014;5:781. [DOI: 10.3389/fpsyg.2014.00781] [PMC4114196]">Dienes 2014</a>; <a href="./references#CD013066-bbs2-0047" title="DienesZ , MclatchieN . Four reasons to prefer Bayesian analyses over significance testing. Psychonomic Bulletin and Review2018;25(1):207-18. [PMID: 28353065]">Dienes 2018</a><a href="./references#CD013066-bbs2-0053" title="GoodmanSN . Toward evidence-based medical statistics. 2: The Bayes factor. Annals of Internal Medicine1999;130(12):1005-13. [PMID: 10383350]">Goodman 1999</a>; <a href="./references#CD013066-bbs2-0054" title="GoodmanSN . Introduction to Bayesian methods I: measuring the strength of evidence. Clinical Trials2005;2(4):282-90. [PMID: 16281426]">Goodman 2005</a>). The Bayes factor is a comparison of how well two hypotheses (the null hypothesis ‒ H0; and the alternative hypothesis ‐ H1) predict the data (<a href="./references#CD013066-bbs2-0053" title="GoodmanSN . Toward evidence-based medical statistics. 2: The Bayes factor. Annals of Internal Medicine1999;130(12):1005-13. [PMID: 10383350]">Goodman 1999</a>). The Bayes factor provides a continuous measure of evidence for H1 over H0. When the Bayes factor is 1, evidence is insensitive, and this means that the data are equally well predicted by both models and the evidence does not favor either model over the other (1 means the data are as well predicted by H1 as H0, so it should not be interpreted as favoring H0; rather the evidence does not point either way). As the Bayes factor increases above 1 (towards infinity) the evidence favors H1 over H0. As the Bayes factor decreases below 1 (towards 0) the evidence favors H0 over H1 (<a href="./references#CD013066-bbs2-0045" title="DienesZ . Understanding Psychology as a Science: An Introduction to Scientific and Statistical Inference. 1st edition. London: Palgrave Macmillan, 2008. [9780230542303]">Dienes 2008</a>; <a href="./references#CD013066-bbs2-0046" title="DienesZ . Using Bayes to get the most out of non-significant results. Frontiers in Psychology2014;5:781. [DOI: 10.3389/fpsyg.2014.00781] [PMC4114196]">Dienes 2014</a>; <a href="./references#CD013066-bbs2-0047" title="DienesZ , MclatchieN . Four reasons to prefer Bayesian analyses over significance testing. Psychonomic Bulletin and Review2018;25(1):207-18. [PMID: 28353065]">Dienes 2018</a>). </p> <p>Despite the use of Bayes factors, we based the conclusions of this Cochrane Review on the Review Manager 5 analysis (<a href="./references#CD013066-bbs2-0097" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013066-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013066-sec-0041"></div> <section id="CD013066-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD013066-sec-0043"> <h4 class="title">Results of the search</h4> <p>The search yielded 1410 references, of which we deemed 18 to be potentially eligible on the basis of title and abstract. Ten trials involving 4543 participants met our inclusion criteria (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). The evidence is current to 29 January 2020. See <a href="#CD013066-fig-0001">Figure 1</a> for details of the flow diagram with the search results and selection of studies. </p> <div class="figure" id="CD013066-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="‐Study flow diagram." data-id="CD013066-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>‐Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013066-sec-0044"> <h4 class="title">Included studies</h4> <p>The trials are described in <a href="./references#CD013066-sec-0148" title="">Characteristics of included studies</a>. Trials varied in size as well as in the characteristics of the included participants, duration of intervention, and drug dosage. </p> <section id="CD013066-sec-0045"> <h5 class="title">Methods</h5> <p>Between 1988 and 2017 (29 years), 10 trials were conducted in nine countries: Canada (<a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>), Germany (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>), India (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>), Iran (<a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>), Japan (<a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>), Portugal (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>), Spain (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>), USA (<a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>), and Venezuela (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>). There were two international trials (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). The number of the centers ranged between 1 and 118. There were six multicenter trials: <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a> (N = 16); <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a> (N = 59), <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a> (N = 63); <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a> (N = 21); <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a> (N = 31); and <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a> (N = 118). Six trials reported the duration of follow‐up, which ranged between 1 and 12 weeks (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Nine trials had two comparison groups (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>), while one trial had four arms (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>). All trials reported the duration of treatment, which ranged between 1 and 12 weeks (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a> tested for superiority, while the rest of the trials specified no type of test. <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a> and <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a> stated the timing for starting citicoline treatment, which remains unknown for the other trials. <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a> reported during the first 24 hours after the onset of symptoms. <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a> noted post‐24 hours after the onset of symptoms. </p> </section> <section id="CD013066-sec-0046"> <h5 class="title">Participants</h5> <p>The trials randomized 4543 participants (mean: 450.3; median: 179; minimum: 40; maximum: 2298). Four trials reported missing data whose percentages of missing outcome data ranged between 1.8% and 19.6% (mean: 13.45%; median: 16.5%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). </p> <p>Eight trials reported the age of participants (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). In six trials, the mean age of participants was 69.27 years old (standard deviation [SD]: 2.05, and median was 68.86) in the citicoline groups while the mean age in the placebo groups was 70.54 years old (SD: 2.02 and median was 70.69) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a> reported that 84.3% and 93.75% of the participants were 40 or more years old in the citicoline and placebo groups, respectively. <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a> stated that 91% and 96.32% of participants were between 50 and 90 years old in the citicoline and placebo groups, respectively. </p> <p>Eight trials reported the sex of participants (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). The average percentage of male participants who received citicoline was 57.34 (median: 54.5) versus a mean of 50.28 (median 48.6) in the placebo group. </p> <p>The description of the relevant clinical variables of the participants varied across the trials. Five trials included participants with a history of TIA (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>), three trials reported a history of stroke or TIA (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>), five trials reported participants with diabetes (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>, <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>), six trials fixed participants with blood hypertension (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012;</a><a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>), two trials recorded participants with a history of smoking (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>), one trial noted a history of hyperlipidemia (<a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>), and three trials included participants with a history of cardiac disorders (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). </p> <p>Of the 10 included trials, all reported the inclusion criteria (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>), and nine stated the exclusion criteria (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). </p> </section> <section id="CD013066-sec-0047"> <h5 class="title">Interventions</h5> <section id="CD013066-sec-0048"> <h6 class="title">Experimental drug</h6> <p>Nine trials used citicoline alone as the experimental group (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). One trial combined citicoline with standard stroke therapy (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). </p> <p>The route of administration of citicoline varied across the included trials: combined i.e. either intravenously or orally (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>), intravenous only (<a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>), and oral (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). The daily total dose of citicoline by any administration route was not similar across the trials ‒ 500 mg, 1000 mg, 2000 mg, and 3000 mg. The duration of administration and the daily total dose of citicoline used by intravenous route was dissimilar: 1000 mg by seven days (<a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>), 1000 mg by 14 days (<a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>), 2000 mg during three days (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>), 2000 mg by five days (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>), and 3000 mg by 10 days (<a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>). Thus, the range of duration of intravenous administration was three to 14 days. Likewise, the duration of administration and the daily total dose of citicoline used by oral route varied: 500 mg for six weeks (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>), 1000 mg during six weeks (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>), 1000 mg during three weeks (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>), 2000 mg by six weeks (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). </p> </section> <section id="CD013066-sec-0049"> <h6 class="title">Control group</h6> <p>Eight trials used placebo as the control group (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Three trials stated that appearance was identical and indistinguishable between the comparison groups (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>)<i>.</i> One trial used physiological saline as placebo (<a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). Two trials used standard or conventional therapy as control group (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>). One trial described the composition of standard stroke therapy used as control (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). </p> <section id="CD013066-sec-0050"> <p><b>Co‐intervention</b></p> <p>Three trials reported using co‐interventions (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). Two trials described the type of co‐intervention (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>); but only one trial reported use of intravenous thrombolysis (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). </p> </section> </section> </section> <section id="CD013066-sec-0051"> <h5 class="title">Outcomes</h5> <p>The mean of the number of the outcomes was 4.6 (range: 1 to 9). Six trials stated which were primary or secondary outcomes (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Of them, five trials selected relevant clinical outcomes as the primary option (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>, <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Four trials assessed the degree of disability or dependence in daily activities according to the modified Rankin scale (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Seven trials appraised the functional recovery with the Barthel Index (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). Four trials evaluated neurological function with the National Institutes of Health Stroke Scale (NIHSS) (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Three trials considered all‐cause mortality as a secondary outcome (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). One trial included adverse events as an outcome (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Six trials included only one primary outcome (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>), and one trial stated four primary outcomes (<a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>). </p> </section> <section id="CD013066-sec-0052"> <h5 class="title">Miscellaneous</h5> <p>Two trials reported the identifier trial number register (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>). Five trials reported the trial conduct data (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). Four trials reported the sample size estimation a priori (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). One trial likely did a sample size estimation before it started (<a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>). Drug companies supported six included trials (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). It remained unknown in four trials (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). One trial declared the role of its sponsor (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Two trials clearly stated financial disclosures (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). At least one author of the following trials was an employee or consultant of the drug company that sponsored the trial (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). </p> <p>One trial stated an amendment of the protocol (<a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). There was no information in terms of the impact of the amendment over the final results. This trial noted no trial number identifier. </p> <p>One trial was stopped on the recommendation of the Data and Safety Monitoring Board at the third interim analysis, because the statistical stopping boundary for futility had been crossed (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). This trial reported the trial identifier number. </p> </section> </section> <section id="CD013066-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded seven RCTs which were conducted without imaging (<a href="./references#CD013066-bbs2-0011" title="Dereux J-F, GalloisP . Comparison of the results with corticotrophin and citicoline in the initial stage of cerebral infarction. Gazette Medicale1987;94(4):82-5. [CN-00324812]">Dereux 1987</a>; <a href="./references#CD013066-bbs2-0011" title="Dereux J-F, GalloisP . Comparison of the results with corticotrophin and citicoline in the initial stage of cerebral infarction. Gazette Medicale1987;94(4):82-5. [CN-00324812]">Dereux 1987</a>; <a href="./references#CD013066-bbs2-0013" title="GoelD . ECCT-HIS. Edaravone-Citicoline comparative trial in head injury and stroke. Available at www.strokecenter.org/trials/clinicalstudies/edaravone-citicoline-comparative-trial-in-head-injury-and-stroke. MittalM , GoelD , BansalKK , PuriP . Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). Journal of the Association of Physicians of India2012;60(11):36-8. [PMID: 23767201]">ECCS‐ AIS 2012</a>; <a href="./references#CD013066-bbs2-0014" title="Garcia PastorA , Diaz OteroF , Gil NunezAC , Villanueva OsorioJA . Tolerability and efficacy of the combination of piracetam and citicoline in acute ischemic stroke. A randomized comparative open study. Stroke2004;35(6):e286. ">Garcia Pastor 2004</a>; <a href="./references#CD013066-bbs2-0015" title="GoasJY , BastardJ , MissoumA . Results after 90 days of stroke treatment with CDP-choline concerning a double-blind test [Bilan a 90 jours du traitement des accidents vasculaires cerebraux par la CDP-choline. A propos d' un essai en double insu]. International Symposium. Brain Suffering and Precursor of Phospholipids. Paris 1980, January 18;109-21.1980:123-8. ">Goas 1980</a>; <a href="./references#CD013066-bbs2-0016" title="MelnikovaEV , ShmoninAA , KulaginPA , StukovaLN , MischenkoKA . Neuroprotection effectiveness depends on the size and location of the ischemic stroke focus. Cerebrovascular Diseases2011;31 Suppl 2:132. ">Melnikova 2011</a>; <a href="./references#CD013066-bbs2-0017" title="PanteleienkoL , SokolovaL . Patients treated with citicoline in acute phase of ischemic stroke report better quality of life. European Journal of Neurology2009;16(S3):412. ">Panteleienko 2009</a>). See <a href="./references#CD013066-sec-0149" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD013066-sec-0054"> <h4 class="title">Studies awaiting classification</h4> <p>We identified one study in this category (<a href="./references#CD013066-bbs2-0018" title="HassanA , HassounHK , SameerA , HadiNR , AllebbanZ . Effect of citicoline on cerebral hemodynamics and vasoreactivity using transcranial doppler in acute ischemic stroke patients: clinical trial. International Journal of Pharmaceutical Research2019;11(2):262-9. [DOI: 10.31838/ijpr/2019.11.02.045]">Hassan 2019</a>). </p> </section> <section id="CD013066-sec-0055"> <h4 class="title">Ongoing trials</h4> <p>We identified two ongoing trials (<a href="./references#CD013066-bbs2-0019" title="AgarwalA , VishnuVY , BhatiaR , GoyalV , SinghMB , JosephL , et al. [Abstract 431] Citicoline in acute ischemic stroke - a randomized control trial. International Journal of Stroke2018;13(2S):104. ">CTRI/2018/02/011900</a>; <a href="./references#CD013066-bbs2-0020" title="Ongoing study. Expected recruitment start date: 20 February 2016Expected recruitment end date: 18 February 2017. Contact author for more information.">IRCT201601289014N90</a>). See <a href="./references#CD013066-sec-0151" title="">Characteristics of ongoing studies</a> table for details. </p> </section> </section> <section id="CD013066-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>We have summarized risks of bias in the included trials in <a href="#CD013066-fig-0002">Figure 2</a> and <a href="#CD013066-fig-0003">Figure 3</a>, and we have provided more details in the <a href="./references#CD013066-sec-0148" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD013066-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD013066-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013066-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD013066-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013066-sec-0057"> <h4 class="title">Allocation</h4> <section id="CD013066-sec-0058"> <h5 class="title">Random sequence generation</h5> <p>We rated one trial as having a low risk of selection bias because the trial authors used a centralized randomization process with an interactive voice response system (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Nine trials had unclear risk of bias for this domain due to the lack of a clear description of how the random sequence generation was conducted (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). </p> </section> <section id="CD013066-sec-0059"> <h5 class="title">Allocation concealment</h5> <p>We considered risk of bias arising from the method of allocation concealment to be low in one trial. This judgment is based on the interactive voice response system used for reducing the risk of selection bias (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Nine trials did not report the randomization process methodology: thus, we considered risk of bias arising from the method of allocation concealment to be unclear (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). </p> </section> </section> <section id="CD013066-sec-0060"> <h4 class="title">Blinding</h4> <section id="CD013066-sec-0061"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>We rated risk of bias due to lack of blinding of participants and personnel as low in four trials as they provide an appropriate description of the blinding: the experimental drug and control were indistinguishable, personnel were masked (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). We judged five trials as unclear risk for performance bias due to the absence of an adequate description for blinding of participants and personnel (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). One trial had a high risk of bias for this domain due to the following description: "the authors evaluated the outcome themselves, were not blinded to the treatment" (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). </p> </section> <section id="CD013066-sec-0062"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>Three trials clearly reported outcome assessment as blinded, and we considered detection bias to be low because the personnel carrying out the clinical assessment were blinded (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). We rated six trials as having an unclear risk of bias for blinding of outcome assessors due to lack of information about the blinding of the personnel (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). We considered one trial to have a high risk of detection bias because it did not report blinding for outcome assessment (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). </p> </section> </section> <section id="CD013066-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>We rated risk of attrition bias as low in five trials (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). Two trials had an unclear risk of bias for this domain: one trial reported no information about this because it was published as an abstract, whereas the other trial assessed physiological outcomes (<a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>: <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>). We considered three trials as having a high risk of bias for attrition bias due to the percentage of dropouts, which were 16%, 23% and 19%, respectively (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>) </p> </section> <section id="CD013066-sec-0064"> <h4 class="title">Selective reporting</h4> <p>We considered seven trials as having a low risk for selective outcome reporting bias due to reported information about the prefixed outcomes for this Cochrane Review. That information allowed us to pool the data (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). We considered one trial as having an unclear risk of bias for this domain; trial information was reported in an abstract (<a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>). We judged two trials as having a high risk of reporting bias because neither appropriate data about outcomes nor information about outcomes required in this Cochrane Review were available (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>). Two trials reported their trial registration number (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>). </p> </section> <section id="CD013066-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>We detected bias either in the presentation of the data or in the design of trials (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007;</a><a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>, <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>), in the measurements and confounding biases due to lack of information regarding the impact of the amendment of the trial protocol (<a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>), funding bias due to many trial authors receiving either consultation fees or honoraria from the trial sponsor, and one trial author was a full‐time employee of the sponsor (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>). We considered two trials as having an unclear risk for other potential sources of bias (funding bias) (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). </p> <p>Based on the protocol for this Cochrane Review, which stated "We will consider trials at low risk of bias to be those that used an adequate system to generate their allocation sequence, had adequate allocation concealment, adequate blinding, adequate handling of incomplete outcome data, were free of selective outcome reporting and were free of other bias", we considered all trials to have a high risk of bias. </p> </section> </section> <section id="CD013066-sec-0066"> <h3 class="title" id="CD013066-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD013066-tbl-0001"><b>Summary of findings 1</b> Citicoline compared with placebo or standard treatment for treating people with acute ischemic stroke</a> </p> <p>The results are based on 4281 randomized participants in nine trials (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). One included trial only supplied information about hemodynamic cerebral outcomes (<a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>). All trials compared citicoline versus placebo or no intervention. <a href="#CD013066-tbl-0002">Table 1</a> shows a summary of meta‐analyses with 95% CI comparing the fixed‐effect with random‐effects models of the intervention results. </p> <div class="table" id="CD013066-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐analyses with 95% CI using either a fixed‐effect or random‐effects model results</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fixed‐effect</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Random‐effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.94, 95% CI 0.83 to 1.07; I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.94, 95% CI 0.83 to 1.07; I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Degree of disability or dependence in daily activities according to the modified Rankin scale </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11, 95% CI 0.97 to 1.26; I² = 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11, 95% CI 0.97 to 1.26; I² = 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe adverse events (Reporting cardiovascular adverse events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.04 95% CI 0.84 to 1.29; I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.04 95% CI 0.84 to 1.28; I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Functional recovery: assessed with the Barthel Index (≥95 points)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.03, 95% CI 0.94 to 1.13; I² = 24%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05, 95% CI 0.93 to 1.17; I² = 24%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological function assessed with the National Institutes of Health Stroke Scale (NIHSS):≤1 points) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.08, 95% CI 0.96 to 1.21; I² = 27%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.09, 95% CI 0.93 to 1.27; I² = 27%</p> </td> </tr> </tbody> </table> </div> <section id="CD013066-sec-0067"> <h4 class="title">Primary</h4> <section id="CD013066-sec-0068"> <h5 class="title">All‐cause mortality</h5> <section id="CD013066-sec-0069"> <h6 class="title">Citicoline versus placebo</h6> <p>A pooled analysis of eight trials found no difference in all‐cause mortality comparing citicoline with placebo (399/2313 [17.3%] versus 379/2049 [18.5%]; RR fixed‐effect 0.94, 95% CI 0.83 to 1.07; I² = 0%; low‐quality evidence due to risk of bias) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>) (<a href="./references#CD013066-fig-0006" title="">Analysis 1.1</a>). Bayes factor was 0.33 which means that the evidence favors moderatelly null hypothesis over alternative hypothesis. Trial Sequential Analysis suggested no more trials are needed (<a href="#CD013066-fig-0004">Figure 4</a>; <a href="./full#CD013066-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD013066-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis for citicoline versus placebo or no intervention on all‐cause mortality. The diversity‐adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 14% from proportion event in control (Pc) group of 18.5% with an alpha of 5% and beta of 20%. Cumulative Z‐curve (blue line) reached futility area after seven trials, which means that no more trials are needed." data-id="CD013066-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-04.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis for citicoline versus placebo or no intervention on all‐cause mortality. The diversity‐adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 14% from proportion event in control (Pc) group of 18.5% with an alpha of 5% and beta of 20%. Cumulative Z‐curve (blue line) reached futility area after seven trials, which means that no more trials are needed. </p> </div> </div> </div> </section> <section id="CD013066-sec-0070"> <h6 class="title">Subgroup analysis</h6> <section id="CD013066-sec-0071"> <p><b>Trials without support from pharmaceutical companies versus trials supported by pharmaceutical companies</b></p> <p>Two trials conducted without support from pharmaceutical companies found no difference comparing citicoline with placebo in terms of all‐cause mortality (13/161 [8.07 %] versus 19/174 [10.91 %]: RR 0.78, 95% CI 0.41 to 1.49; I² = 0%) (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). Pooled data of six trials supported by pharmaceutical companies showed no difference comparing citicoline with placebo in terms of all‐cause mortality (386/2152 [17.93 %] versus 360/1875 [19.2%]: RR 0.95, 95% CI 0.83 to 1.08; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Test for subgroup differences: Chi² = 0.34, df = 1 (P = 0.56), I² = 0%. See <a href="./references#CD013066-fig-0007" title="">Analysis 1.2</a>. </p> </section> <section id="CD013066-sec-0072"> <p><b>Trials with ≤ 200 participants versus trials with &gt; 200 participants</b></p> <p>Pooled analysis of three trials which included 200 or fewer participants showed no difference comparing citicoline with placebo in terms of all‐cause mortality (20/118 [16.94%] versus 17/122 [13.93%]: RR 1.26, 95% CI 0.70 to 2.29; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Pooled data of five trials which recruited more than 200 participants showed no difference comparing citicoline versus placebo in terms of all‐cause mortality (379/2195 [17.26%] versus 362/1927 [18.78%]: RR 0.93, 95% CI 0.81 to 1.06; I² = 0%) (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). Test for subgroup differences: Chi² = 0.99, df = 1 (P = 0.32), I² = 0%. See <a href="./references#CD013066-fig-0008" title="">Analysis 1.3</a>. </p> </section> </section> <section id="CD013066-sec-0073"> <h6 class="title">Sensitivity analyses</h6> <section id="CD013066-sec-0074"> <p><b>Assessing the impact of missing outcome data</b></p> <p>Meta‐analysis of four trials not reporting missing data showed no difference comparing citicoline versus placebo in terms of all‐cause mortality (159/942 [16.87%] versus 117/673 [17.38%]; RR 0.99, 95% CI 0.79 to 1.23; I² = 0%) (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). Pooled data of four trials reporting missing data showed no difference comparing citicoline versus placebo in terms of all‐cause mortality (240/1371 [17.5%] versus 262/1376 [19.04%]; RR 0.92, 95% CI 0.78 to 1.07; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Test for subgroup differences: Chi² = 0.28, df = 1 (P = 0.59); I² = 0%. See <a href="./references#CD013066-fig-0009" title="">Analysis 1.4</a>. </p> </section> <section id="CD013066-sec-0075"> <p><b>Assessing the impact of the missing outcome data: best‐case scenario</b></p> <p>Pooling of four trials without missing data found no difference between comparison groups in relation to all‐cause mortality (RR 0.99, 95% 0.80 to 1.24; I² = 0%) (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). Meta‐analysis of four trials reporting missing data showed a reduction of 58% of the risk of all‐cause mortality with citicoline use versus placebo use (RR 0.42, 95% CI 0.37 to 0.49; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Test for subgroup differences: Chi² = 41.51, df = 1 (P &lt; 0.00001); I² = 97.6%. See <a href="./references#CD013066-fig-0010" title="">Analysis 1.5</a>. </p> </section> <section id="CD013066-sec-0076"> <p><b>Assessing the impact of the missing outcome data: worst‐case scenario</b></p> <p>In relation to all‐cause mortality a pool of four trials without missing data found no difference between comparison groups (RR 0.99, 95% 0.79 to 1.23; I² = 0%) (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). Meta‐analysis of four trials reporting missing data found an increase of 104% of the risk of all‐cause mortality in the citicoline group compared with placebo (RR 2.04, 95% CI 1.79 to 2.332; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Test for subgroup differences: Chi² = 41.51, df = 1 (P &lt; 0.00001); I² = 97.6%. See <a href="./references#CD013066-fig-0011" title="">Analysis 1.6</a>. </p> </section> <section id="CD013066-sec-0077"> <p><b>Assessing the impact of the missing outcome data: the Gamble‐Hollis analysis</b></p> <p>With regard to all‐cause mortality, pooling four trials without missing data found no difference between comparison groups (RR 0.99, 95% 0.79 to 1.23; I² = 0%) (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). Meta‐analysis of four trials found no difference between comparison groups (RR 0.86, 95% CI 0.45 to 1.64; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Test for subgroup differences: Chi² = 0.15, df = 1 (P = 0.70); I² = 0%. See <a href="./references#CD013066-fig-0012" title="">Analysis 1.7</a>. </p> </section> </section> </section> <section id="CD013066-sec-0078"> <h5 class="title">Degree of disability or dependence in daily activities</h5> <section id="CD013066-sec-0079"> <h6 class="title">Citicoline versus placebo</h6> <p>Four trials showed that citicoline may not increase the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, according to the Rankin Scale (414/1906 [21.7%] versus 339/1762 [19.2%]; RR fixed‐effect 1.11, 95% CI 0.97 to 1.26; I² = 1%; low‐quality evidence due to risk of bias) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>) (<a href="./references#CD013066-fig-0013" title="">Analysis 1.8</a>). Bayes factor was 1.81 which means that the evidence anecdotally favors alternative hypothesis over null hypothesis. Trial Sequential Analysis suggested no more trials are required (<a href="#CD013066-fig-0005">Figure 5</a>; <a href="./full#CD013066-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD013066-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis for citicoline versus placebo or no intervention on degree of disability or dependence in daily activities according to the modified Rankin scale. The diversity‐adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 19% from proportion event in control (Pc) group of 19.95% with an alpha of 5% and beta of 20%. Cumulative Z‐curve (blue line) reached futility area after four trials, which means that no more trials are needed." data-id="CD013066-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-05.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis for citicoline versus placebo or no intervention on degree of disability or dependence in daily activities according to the modified Rankin scale. The diversity‐adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 19% from proportion event in control (Pc) group of 19.95% with an alpha of 5% and beta of 20%. Cumulative Z‐curve (blue line) reached futility area after four trials, which means that no more trials are needed. </p> </div> </div> </div> </section> <section id="CD013066-sec-0080"> <h6 class="title">Subgroup analysis</h6> <section id="CD013066-sec-0081"> <p><b>Trials with ≤ 200 participants versus trials with &gt; 200 participants</b></p> <p>One trial with 200 or fewer participants found no difference in the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, according to the Rankin Scale (13/38 [34.2%] versus 10/39 [25.6%]; RR 1.33, 95% CI 0.67 to 2.67) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>). A meta‐analysis including three trials that included 200 or more participants showed no difference comparing citicoline with placebo in the proportion of patients with a moderate or lower degree of disability or dependence (401/1868 [34.2%] versus 329/1723 [25.6%]; RR 1.10, 95% CI 0.96 to 1.25; I² = 27%) (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). Test for subgroup differences: Chi² = 0.29, df = 1 (P = 0.59); I² = 0%. See <a href="./references#CD013066-fig-0014" title="">Analysis 1.9</a>. </p> </section> </section> <section id="CD013066-sec-0082"> <h6 class="title">Sensitivity analysis</h6> <section id="CD013066-sec-0083"> <p><b>Assessing the impact of missing outcome data</b></p> <p>Meta‐analysis of two trials which did not report missing data showed no difference comparing citicoline with placebo in the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, according to the Rankin Scale (190/720 [23.4%] versus 121/573 [21.1%]; RR 1.23, 95% CI 1.01 to 1.50; I² = 0%) (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). Pooled data of two trials that reported missing data found no difference comparing citicoline versus placebo in the proportion of patients with a moderate or lower degree of disability or dependence (224/1186 [18.9%] versus 218/1189 [18.3%]; RR 1.03, 95% CI 0.87 to 1.22; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Test for subgroup differences: Chi² = 1.74, df = 1 (P = 0.19); I² = 42.4%. See <a href="./references#CD013066-fig-0015" title="">Analysis 1.10</a>. </p> </section> <section id="CD013066-sec-0084"> <p><b>Assessing the impact of missing outcome data: best‐case scenario</b></p> <p>According to a best‐case scenario assessment of the impact of missing data, there was no difference in two trials which did not report missing data comparing citicoline with placebo regarding the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, according to the Rankin Scale (RR 1.23, 95% CI 1.00 to 1.50; I² = 0%) (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). By contrast, meta‐analysis of two trials that reported missing data showed that citicoline may result in a slight reduction in the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo (RR 0.44, 95% CI 0.39 to 0.51; I² = 67%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Test for subgroup differences: Chi² = 67.32, df = 1 (P &lt; 0.00001); I² = 98.5%. See <a href="./references#CD013066-fig-0016" title="">Analysis 1.11</a>. </p> </section> <section id="CD013066-sec-0085"> <p><b>Assessing the impact of missing outcome data: worst‐case scenario</b></p> <p>According to a worst‐case scenario assessment of the impact of missing data, there was no difference in two trials which did not report missing data comparing citicoline with placebo regarding the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, according to the Rankin Scale (RR 1.23, 95% CI 1.00 to 1.50; I² = 0%) (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). Pooled data of two trials reporting missing data showed that citicoline may result in an increase in the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo (RR 2.33, 95% CI 2.03 to 2.69; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Test for subgroup differences: Chi² = 26.45, df = 1 (P &lt; 0.00001); I² = 96.2%. See <a href="./references#CD013066-fig-0017" title="">Analysis 1.12</a>. </p> </section> <section id="CD013066-sec-0086"> <p><b>Assessing the impact of missing outcome data: the Gamble‐Hollis analysis</b></p> <p>An assessment of the impact of missing outcome data according the Gamble‐Hollis analysis showed no difference comparing citicoline with placebo in the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, neither in trials which did not report missing data (RR 1.23, 95% CI 1.00 to 1.50; I² = 0%) (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>), nor in those reporting missing data (RR 1.14, 95% CI 0.54 to 2.42; I² = 0%) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). Test for subgroup differences: Chi² = 0.03, df = 1 (P = 0.86); I² = 0%. See <a href="./references#CD013066-fig-0018" title="">Analysis 1.13</a>. </p> </section> </section> </section> </section> <section id="CD013066-sec-0087"> <h4 class="title">Secondary</h4> <section id="CD013066-sec-0088"> <h5 class="title">Adverse events</h5> <section id="CD013066-sec-0089"> <h6 class="title">Citicoline versus placebo</h6> <section id="CD013066-sec-0090"> <p><b>Severe adverse events</b></p> <p>Pooled analyses either with three or two trials found no difference comparing citicoline versus placebo in terms of the following severe adverse events. </p> <p> <ul id="CD013066-list-0011"> <li> <p>Cardiovascular (RR 1.04, 95% CI 0.84 to 1.29; 299 events, 3591 participants; I² = 0%; low‐quality evidence due to risk of bias and imprecision (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). </p> </li> <li> <p>Central nervous system (including hemorrhagic or ischemic stroke) (RR 1.30, 95% CI 1.07 to 1.59; 406 events, 3591 participants; I² = 93%; low‐quality evidence due to risk of bias and imprecision (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). </p> </li> <li> <p>Respiratory (including pneumonia) (RR 1.01, 95% CI 0.78 to 1.31; 406 events, 3591 participants; I² = 0%; low‐quality evidence due to risk of bias and imprecision (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). </p> </li> <li> <p>Gastrointestinal (RR 0.64, 95% CI 0.40 to 1.00; 65 events, 1370 participants; I² = 69%; low‐quality evidence due to risk of bias and imprecision (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). </p> </li> <li> <p>Musculoskeletal (RR 1.52, 95% CI 0.50 to 4.60; 15 events, 1293 participants; I² = 0%; low‐quality evidence due to risk of bias and imprecision (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>). </p> </li> <li> <p>Renal and urologic disorders (RR 2.04, 95% CI 0.99 to 4.22; 39 events, 1560 participants; I² = 0%; low‐quality evidence due to risk of bias and imprecision (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). </p> </li> <li> <p>Hematological disorders (RR 1.27, 95% CI 0.46 to 3.51; 16 events, 1560 participants; I² = 0%; low‐quality evidence due to risk of bias and imprecision (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). </p> </li> </ul> </p> <p>Test for subgroup differences: Chi² = 12.54, df = 7 (P = 0.08); I² = 44.2%. See <a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>. <a href="./full#CD013066-tbl-0001">summary of findings Table 1</a>.<br/><br/>One trial reporting severe hepatic dysfunction showed no difference between comparison groups (RR 1.47, 95% CI 0.48 to 4.49; 7 events, 267 participants; I² = 0%; low‐quality evidence due to risk of bias and imprecision (<a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). </p> </section> <section id="CD013066-sec-0091"> <p><b>Non‐severe adverse events</b></p> <p>One trial including 2298 participants supplied data regarding non‐severe adverse events (<a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). There was no difference between comparison groups regarding cardiac disorders (RR 0.94, 95% CI 0.82 to 1.08; 572 events), pyrexia (RR 1.02, 95% CI 0.87 to 1.19; 512 events), constipation (RR 1.03, 95% CI 0.88 to 1.20; 484 events), urinary tract infections (RR 1.06, 95% CI 0.89 to 1.26; 426 events), headache (RR 0.96, 95% CI 0.79 to 1.18; 314 events), nausea and vomiting symptoms (RR 0.95, 95% CI 0.77 to 1.16; 315 events), agitation (RR 1.20, 95% CI 0.94 to 1.54; 229 events), hemorrhagic transformation of the stroke (RR 0.98, 95% CI 0.74 to 1.29; 184 events), pneumonia (RR 1.02, 95% CI 0.73 to 1.41; 135 events), and hypotension (RR 0.92, 95% CI 0.63 to 1.36; 100 events). See <a href="./references#CD013066-fig-0020" title="">Analysis 1.15</a>. We rated the quality of evidence for non‐severe adverse events as low due to risk of bias and imprecision. </p> <p><a href="#CD013066-tbl-0003">Table 2</a> shows the information about harms as reported in the trials. </p> <div class="table" id="CD013066-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Included trials: description of the harms</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Harms</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "A patient in the active group with a history of gastric ulcer presented a digestive bleeding and the treatment was discontinued; no adverse effects were reported in the placebo group." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "Only two adverse events were seen seen in greater incidence in the citicoline group: edema of the extremities ( p ≤ 0.05) and back pain (p ≤ 0.10)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "In addition it was tolerated very well."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriate report (<a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See <a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a> for severe adverse events<br/>Quote: "No serious adverse effects were related to treatment with CDP‐choline in any patient with cerebral infarction." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "There were no serious adverse events reasonably attributed to the study medication. The only adverse events that were significantly different between the treatment groups and placebo group were dizziness and accidental injury, primarily related to falling. Of the patients who fell, only one (2000 mg group) was of clinical significance (associated with hip fracture), whereas the remainder were minor in nature. It should be noted that the patients who were experiencing dizziness were not the same patients who experienced accidental injuries." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriate report (<a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriate report (<a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>) </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section id="CD013066-sec-0092"> <h5 class="title">Functional recovery</h5> <section id="CD013066-sec-0093"> <h6 class="title">Citicoline versus placebo</h6> <p>One trial assessing functional recovery with the a cut‐off in the Barthel Index of 50 points found no difference comparing citicoline with placebo (16/38 [42.1%] versus 13/39 [33.3%]; RR fixed‐effect 1.26, 95% CI 0.71 to 2.26; low‐quality evidence due to risk of bias and imprecision) (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>). Four trials assessing the functional recovery with a cut‐off in the Barthel Index of 95 or more points found no difference comparing citicoline with placebo (676/2062 [32.8%] versus 549/1788 [30.7%]; RR 1.03, 95% CI 0.94 to 1.13; I² = 24%; low‐quality evidence due to risk of bias). The Bayes factor was 0.75 which means that the evidence favors moderatelly the null hypothesis over the alternative hypothesis (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>). One trial with a cut‐off in the Barthel Index of 85 to 100 points found no difference favoring citicoline versus placebo (10/28 [35.7%] versus 4/35 [11.4%]; RR 3.13, 95% CI 1.10 to 8.91; low‐quality evidence due to risk of bias and imprecision) (<a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>). Test for subgroup differences: Chi² = 4.69, df = 2 (P = 0.10), I² = 57.3%. See <a href="./references#CD013066-fig-0021" title="">Analysis 1.16</a>. <a href="./full#CD013066-tbl-0001">summary of findings Table 1</a>. </p> <p>Based on a P value &lt; 0.05, <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a> reported improvements of functional recovery in a narrative way. </p> </section> </section> <section id="CD013066-sec-0094"> <h5 class="title">Neurological function</h5> <section id="CD013066-sec-0095"> <h6 class="title">Citicoline versus placebo</h6> <p>Five trials assessed neurological function with the National Institutes of Health Stroke Scale at a cut‐off point of ≤1 points. A pooled analysis of these trials showed that citicoline, compared to placebo, may not increase the proportion patients with minor impairment (514/2114 [24.3%] versus 412/1836 [22.4%]; RR fixed‐effect 1.08, 95% CI 0.96 to 1.21; I² = 27%; low‐quality evidence due to risk of bias). The Bayes factor was 1.32 which means that the evidence anecdotally favors the alternative hypothesis over the null hypothesis (<a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). See <a href="./references#CD013066-fig-0022" title="">Analysis 1.17</a>. <a href="./full#CD013066-tbl-0001">summary of findings Table 1</a>. </p> </section> </section> <section id="CD013066-sec-0096"> <h5 class="title">Quality of life</h5> <section id="CD013066-sec-0097"> <h6 class="title">Citicoline versus placebo</h6> <p>None of the trials reported information about this outcome. See <a href="./full#CD013066-tbl-0001">summary of findings Table 1</a>. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013066-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013066-sec-0098"></div> <section id="CD013066-sec-0099"> <h3 class="title" id="CD013066-sec-0099">Summary of main results</h3> <p>This Cochrane Review about citicoline for treating people with acute ischemic stroke includes 10 trials randomizing 4281 participants. These trials evaluated citicoline that was given orally, intravenously or both compared with placebo or standard care therapy. Citicoline doses ranged between 500 and 2000 mg per day. Four out of 10 trials reported an a priori sample size estimation. Drug companies sponsored six trials. There were six multicenter trials, of which two were international. Trials were conducted in nine countries in either outpatient (ambulatory) or inpatient settings. Overall, we assessed these trials as having a high risk of bias. The main results yielded from the meta‐analysis are as follows. </p> <p> <ul id="CD013066-list-0012"> <li> <p>None of the pooled analyses found differences between citicoline and their comparison groups regarding all‐cause mortality, disability or dependence (according to &lt; 3 scores in the modified Rankin scale), functional recovery (assessed with the Barthel Index), neurological impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale), or severe adverse events. Quality of evidence for effects of interventions was low due to either limitations in the design and execution of the trials or very low number of events and smallness of sample sizes. </p> </li> <li> <p>One trial reporting information about non‐severe adverse events identified no differences. The quality of evidence was low due to high risk of bias and a very low number of events. <a href="#CD013066-tbl-0003">Table 2</a> shows how such harmful events were reported in the included trials. </p> </li> <li> <p>Two trials pooled not using the Barthel Index at a cut‐off point of 50 points or a cut‐off point of 85 to 100 points found no difference between comparison groups and the evidence was of low quality due to high risk of bias and very low number of events and smallness of sample sizes. </p> </li> <li> <p>No trial assessed the effects of interventions over the quality of life.</p> </li> </ul> </p> <p>See <a href="./full#CD013066-tbl-0001">summary of findings Table 1</a> for details. </p> </section> <section id="CD013066-sec-0100"> <h3 class="title" id="CD013066-sec-0100">Overall completeness and applicability of evidence</h3> <p>This Cochrane Review has not found evidence that citicoline is useful for treating people with acute ischemic stroke. Although there were no trials at low risk of bias, this statement is based on either sensitivity analyses or subgroup analyses from trials that included a broad range of participants with different co‐morbidities who received different treatment approaches. Furthermore, the Trial Sequential Analyses for citicoline versus placebo or no intervention showed that no more studies are required for assessing either all‐cause mortality or degree of disability or dependence in daily activities according to the modified Rankin scale. </p> <p>Only 40% of the trials included in this Cochrane Review reported sample size estimation a priori (<a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>), which coincides with findings by other researchers (<a href="./references#CD013066-bbs2-0036" title="ChanAW , HrobjartssonA , JorgensenKJ , GotzschePC , AltmanDG . Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ2008;337:a2299. [PMID: 19056791]">Chan 2008</a>; <a href="./references#CD013066-bbs2-0088" title="MhaskarR , DjulbegovicB , MagazinA , SoaresHP , KumarA . Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. Journal of Clinical Epidemiology2012;65(6):602-9. [PMID: 22424985]">Mhaskar 2012</a>). Therefore, the clinical significance of the trials without a sample size estimation is uncertain (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>). Also, these trials reported no threshold for detecting differences between comparison groups, which is a component for estimating the sample size (<a href="./references#CD013066-bbs2-0086" title="MaschaEJ , VetterTR . Significance, errors, power, and sample size: The blocking and tackling of statistics. Anesthesia and Analgesia2018;126(2):691-8. [PMID: 29346210]">Mascha 2018</a>; <a href="./references#CD013066-bbs2-0107" title="SormaniMP . The most frequently asked question to a statistician: the sample size. Multiple Sclerosis2017;23(5):644-6. [PMID: 28273773]">Sormani 2017</a>). </p> <p><a href="#CD013066-tbl-0004">Table 3</a> provides details related to the sample size, number of outcomes, and conclusions of the included trials in this Cochrane Review (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a>; <a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a>; <a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a>; <a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a>; <a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>; <a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Another pitfall found in the included trials is that one out of six trials that did not do a formal estimation of sample size reported two or more outcomes (<a href="#CD013066-tbl-0004">Table 3</a>), which could yield an increasing risk of false positives and false negatives: family‐wise error rate (<a href="./references#CD013066-bbs2-0044" title="DelormeP , deMicheauxPL , LiquetB , RiouJ . Type-II generalized family-wise error rate formulas with application to sample size determination. Statistics in Medicine2016;35(16):2687-714. [PMID: 26914402]">Delorme 2016</a>; <a href="./references#CD013066-bbs2-0105" title="SennS , BretzF . Power and sample size when multiple endpoints are considered. Pharmaceutical Satistics2007;6(3):161-70. [PMID: 17674404]">Senn 2007</a>; <a href="./references#CD013066-bbs2-0115" title="van derLaanMJ , DudoitS , PollardKS . Augmentation procedures for control of the generalized family-wise error rate and tail probabilities for the proportion of false positives. Statistical Applications in Genetics and Molecular Biology2004;3:Article 15. [PMID: 16646793]">van der Laan 2004</a>). By using Trial Sequential Analysis this review has determined an optimal information size providing sufficient protection to reduce overestimation or random errors (<a href="./references#CD013066-bbs2-0114" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PloS One2011;6(10):e25491. [PMID: 22028777]">Thorlund 2011b</a>). </p> <div class="table" id="CD013066-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sample size estimation a priori and trial's conclusions</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sample size estimation a priori/randomized participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of reported outcomes/number of comparison groups</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prefixed primary outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Was clinical primary</b> <b>outcome?</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Statistical power</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Alpha</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Type of statistical test (1‐tailed or 2‐tailed)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial's conclusions</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "The Citicholine was superior to placebo to improve the percentage of patients that can be assisted to if same after an episode of ictus acute, taken place by the occlusion of the cerebral media artery." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (with multiple correlations)/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "We found a significant inverse relationship between lesion volume change over 12 weeks as measured by MRI and clinical outcome for ischemic stroke. This relationship supports the role of DWI as a surrogate marker of clinically meaningful lesion progression in stroke clinical trials. The hypothesis that citicoline reduces lesion growth and improves clinical outcome will be tested further." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "It was recognized that this study would be underpowered to<br/>detect a difference in clinical outcome." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Treatment with citicoline in patients of stroke, presenting within 48 h of onset, increases the probability of recovery and a favorable outcome at the end of the 1<sup>st</sup> and the 3<sup>rd</sup> month in all stroke groups. A large randomized control trial is necessary in near future to support the results of this study." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "CDP‐choline seemed better than the placebo, leading to improvement as quantified by the GCS (p&lt;.05), Mathew's Scale (p&lt;:01), Barthel's Scale (p&lt;.05) and the Red Cross Scales (p&lt;.05)." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Under the circumstances of the ICTUS trial, citicoline is not efficacious in the treatment of moderate to‐ severe acute ischaemic stroke." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Prescription of citicoline for treatment of acute ischemic stroke is associated with hemodynamic changes in cerebral arteries. This finding can be one of the citicoline's mechanisms of action in ischemic stroke process." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "The group treated with CDP‐choline showed significant improvements in level of consciousness compared with the placebo‐treated group, and CDP‐choline was an entirely safe treatment." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "The results of this study indicate that citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke who were enrolled in this trial." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DWI: diffusion‐weighted magnetic resonance imaging<br/>GCS: Glasgow Coma scale.<br/>MRI: magnetic resonance imaging<br/>NA: not applicable </p> </div> </div> <p>We were not able to do show a meta‐analysis about the adverse events or harms with all the included trials. This could be for many reasons: a lack of standardization of definitions and analyses of the adverse events (<a href="./references#CD013066-bbs2-0073" title="IoannidisJP . How to make more published research true. PLoS Medicine2014;11(10):e1001747. [PMID: 25334033]">Ioannidis 2014</a>), the shortage of homogeneity and plenty of variability in reporting harm data (<a href="./references#CD013066-bbs2-0071" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737-9. [PMID: 19858427]">Ioannidis 2009</a>; <a href="./references#CD013066-bbs2-0093" title="PitrouI , BoutronI , AhmadN , RavaudP . Reporting of safety results in published reports of randomized controlled trials. Archives of Internal Medicine2009;169(19):1756-61. [PMID: 19858432]">Pitrou 2009</a>), the different times for conducting the trials (1988 to 2017), and failure to collect the harm data (<a href="./references#CD013066-bbs2-0021" title="AllenEN , ChandlerCI , MandimikaN , LeisegangC , BarnesK . Eliciting adverse effects data from participants in clinical trials. Cochrane Database of Systematic Reviews2018, Issue 1. Art. No: MR000039. [DOI: 10.1002/14651858.MR000039.pub2] [PMID: 29372930]">Allen 2018</a>; <a href="./references#CD013066-bbs2-0124" title="YangF , WittesJ , PittB . Beware of on-treatment safety analyses. Clinical Trials2019;16(1):63-70. [PMID: 30445833]">Yang 2019</a>). <a href="#CD013066-tbl-0003">Table 2</a> shows how this issue was reported in each included trial. </p> </section> <section id="CD013066-sec-0101"> <h3 class="title" id="CD013066-sec-0101">Quality of the evidence</h3> <p><a href="./full#CD013066-tbl-0001">summary of findings Table 1</a> shows the quality of evidence for citicoline compared with placebo or standard treatment for treating people with acute ischemic stroke. We considered the quality of the evidence available for this comparison as low. This was due to unclear risk of bias in almost all domains of the trials for the outcomes assessed (all‐cause mortality, degree of disability or dependence in daily activities, functional recovery, and neurological function). Due to limitations in design, execution, and imprecision (small low number of events leading to wide confidence intervals), the quality of evidence for serious adverse events was rated as low. </p> </section> <section id="CD013066-sec-0102"> <h3 class="title" id="CD013066-sec-0102">Potential biases in the review process</h3> <p>Both outcome reporting and attrition biases act as information suppressors, as does publication bias of any etiology (<a href="./references#CD013066-bbs2-0072" title="IoannidisJP . Meta-research: The art of getting it wrong. Research synthesis methods2010;1(3-4):169-84. [PMID: 26061464]">Ioannidis 2010</a>). Based on this argument, the question arises: could the amount of effect of the intervention have been different if the percentage of those information suppressor biases had been different? It should be noted that there were three trials with loss of information that fluctuated between 16% and 23% (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). Two of them were small trials, and therefore low powered for detecting differences between citicoline and the control groups (<a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a>; <a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a>). In addition, two clinical trials supplied no information to the preset outcomes of this Cochrane Review (<a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>). If, on the basis of not providing information to the outcomes of this Cochrane Review, we had excluded two trials (<a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a>; <a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a>), the effect of the intervention would have been the same. This is explained by the fact that none of them provided information about the relevant pre‐established clinical outcomes in this review. This would have introduced publication bias, however, from which this review is at low risk. This Cochrane Review rated 30% of trials as having unclear or high risk of selective outcome reporting bias and 50% of trials as having unclear or high risk of attrition bias (<a href="#CD013066-fig-0002">Figure 2</a>; <a href="#CD013066-fig-0003">Figure 3</a>). This is a limitation which is described and reflected in the quality of the evidence assessment (<a href="./full#CD013066-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013066-sec-0103"> <h3 class="title" id="CD013066-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>Our results are similar to six non‐Cochrane Reviews and pooled analyses (<a href="./references#CD013066-bbs2-0041" title="DávalosA , CastilloJ , Alvarez-SabinJ , SecadesJJ , MercadalJ , LopezS , et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke2002;33(12):2850-7. [PMID: 12468781]">Dávalos 2002</a>; <a href="./references#CD013066-bbs2-0078" title="LeeM , TowfighiA , SaverJL . Choline precursors in acute and subacute ischemic and hemorrhagic stroke: an updated meta-analysis of randomized controlled trials. Stroke2010;41 (4):e263 (Abstract 33).">Lee 2010</a>; <a href="./references#CD013066-bbs2-0081" title="LiuL , ShiZ , YanQ , GuoJ . Cytidine diphosphate choline for acute stroke: a meta-analysis. Chinese Journal of Evidence-based Medicine2011;11(4):404-12.">Liu 2011</a>; <a href="./references#CD013066-bbs2-0100" title="SaverJL , WilterdinkJ . Choline precursors in acute and subacute human stroke: a meta-analysis. Stroke2002;33(1):353.">Saver 2002</a>; <a href="./references#CD013066-bbs2-0104" title="SecadesJJ , Alvarez-SabinJ , CastilloJ , Diez-TejedorE , Martinez-VilaE , RiosJ , et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. Journal of Stroke and Cerebrovascular Diseases2016;25(8):1984-96. [PMID: 27234918]">Secades 2016</a>; <a href="./references#CD013066-bbs2-0106" title="ShiPY , ZhouXC , YinXX , XuLL , ZhangXM , BaiHY . Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology. Medical Sciences2016;36(2):270-7. [MEDLINE: 27072975 ]">Shi 2016</a>). We identified differences in their eligibility criteria with respect to our Cochrane Review: 1) participants suffering ischemic and hemorrhagic stroke (<a href="./references#CD013066-bbs2-0078" title="LeeM , TowfighiA , SaverJL . Choline precursors in acute and subacute ischemic and hemorrhagic stroke: an updated meta-analysis of randomized controlled trials. Stroke2010;41 (4):e263 (Abstract 33).">Lee 2010</a>; <a href="./references#CD013066-bbs2-0106" title="ShiPY , ZhouXC , YinXX , XuLL , ZhangXM , BaiHY . Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology. Medical Sciences2016;36(2):270-7. [MEDLINE: 27072975 ]">Shi 2016</a>); 2) inclusion of non‐RCTs (<a href="./references#CD013066-bbs2-0078" title="LeeM , TowfighiA , SaverJL . Choline precursors in acute and subacute ischemic and hemorrhagic stroke: an updated meta-analysis of randomized controlled trials. Stroke2010;41 (4):e263 (Abstract 33).">Lee 2010</a>; <a href="./references#CD013066-bbs2-0104" title="SecadesJJ , Alvarez-SabinJ , CastilloJ , Diez-TejedorE , Martinez-VilaE , RiosJ , et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. Journal of Stroke and Cerebrovascular Diseases2016;25(8):1984-96. [PMID: 27234918]">Secades 2016</a>); 3) use of different scales for assessing clinical benefits of citicoline (<a href="./references#CD013066-bbs2-0104" title="SecadesJJ , Alvarez-SabinJ , CastilloJ , Diez-TejedorE , Martinez-VilaE , RiosJ , et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. Journal of Stroke and Cerebrovascular Diseases2016;25(8):1984-96. [PMID: 27234918]">Secades 2016</a>); 4) RCTs with no imaging confirmation of stroke (<a href="./references#CD013066-bbs2-0104" title="SecadesJJ , Alvarez-SabinJ , CastilloJ , Diez-TejedorE , Martinez-VilaE , RiosJ , et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. Journal of Stroke and Cerebrovascular Diseases2016;25(8):1984-96. [PMID: 27234918]">Secades 2016</a>; <a href="./references#CD013066-bbs2-0106" title="ShiPY , ZhouXC , YinXX , XuLL , ZhangXM , BaiHY . Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology. Medical Sciences2016;36(2):270-7. [MEDLINE: 27072975 ]">Shi 2016</a>); 5) forest plot using the same placebo group three times in different subgroups for the same outcome (<a href="./references#CD013066-bbs2-0106" title="ShiPY , ZhouXC , YinXX , XuLL , ZhangXM , BaiHY . Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology. Medical Sciences2016;36(2):270-7. [MEDLINE: 27072975 ]">Shi 2016</a>); and 6) use of odds ratio for measuring treatment effect (<a href="./references#CD013066-bbs2-0041" title="DávalosA , CastilloJ , Alvarez-SabinJ , SecadesJJ , MercadalJ , LopezS , et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke2002;33(12):2850-7. [PMID: 12468781]">Dávalos 2002</a>; <a href="./references#CD013066-bbs2-0104" title="SecadesJJ , Alvarez-SabinJ , CastilloJ , Diez-TejedorE , Martinez-VilaE , RiosJ , et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. Journal of Stroke and Cerebrovascular Diseases2016;25(8):1984-96. [PMID: 27234918]">Secades 2016</a>; <a href="./references#CD013066-bbs2-0106" title="ShiPY , ZhouXC , YinXX , XuLL , ZhangXM , BaiHY . Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology. Medical Sciences2016;36(2):270-7. [MEDLINE: 27072975 ]">Shi 2016</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013066-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-FIG-01" target="_blank"><b></b></a></p> </div><img alt="‐Study flow diagram." data-id="CD013066-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>‐Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD013066-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD013066-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis for citicoline versus placebo or no intervention on all‐cause mortality. The diversity‐adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 14% from proportion event in control (Pc) group of 18.5% with an alpha of 5% and beta of 20%. Cumulative Z‐curve (blue line) reached futility area after seven trials, which means that no more trials are needed." data-id="CD013066-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-04.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial Sequential Analysis for citicoline versus placebo or no intervention on all‐cause mortality. The diversity‐adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 14% from proportion event in control (Pc) group of 18.5% with an alpha of 5% and beta of 20%. Cumulative Z‐curve (blue line) reached futility area after seven trials, which means that no more trials are needed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-04.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis for citicoline versus placebo or no intervention on degree of disability or dependence in daily activities according to the modified Rankin scale. The diversity‐adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 19% from proportion event in control (Pc) group of 19.95% with an alpha of 5% and beta of 20%. Cumulative Z‐curve (blue line) reached futility area after four trials, which means that no more trials are needed." data-id="CD013066-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-05.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial Sequential Analysis for citicoline versus placebo or no intervention on degree of disability or dependence in daily activities according to the modified Rankin scale. The diversity‐adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 19% from proportion event in control (Pc) group of 19.95% with an alpha of 5% and beta of 20%. Cumulative Z‐curve (blue line) reached futility area after four trials, which means that no more trials are needed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-FIG-05.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 1: All‐cause mortality" data-id="CD013066-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 2: All‐cause mortality: subgroup analysis" data-id="CD013066-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 2: All‐cause mortality: subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 3: All‐cause mortality: subgroup analysis" data-id="CD013066-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 3: All‐cause mortality: subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 4: All‐cause mortality: sensitivity analysis: impact of missing outcome data" data-id="CD013066-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 4: All‐cause mortality: sensitivity analysis: impact of missing outcome data </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 5: All‐cause mortality: sensitivity analysis: best‐case scenario" data-id="CD013066-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 5: All‐cause mortality: sensitivity analysis: best‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 6: All‐cause mortality: sensitivity analysis: worst‐case scenario" data-id="CD013066-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 6: All‐cause mortality: sensitivity analysis: worst‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 7: All‐cause mortality: sensitivity analysis: the Gamble‐Hollis analysis" data-id="CD013066-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 7: All‐cause mortality: sensitivity analysis: the <i>Gamble‐Hollis</i> analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 8: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale)" data-id="CD013066-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 8: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 9: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): subgroup analysis" data-id="CD013066-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 9: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 10: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: impact of missing outcome data" data-id="CD013066-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 10: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: impact of missing outcome data </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 11: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: best‐case scenario" data-id="CD013066-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 11: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: best‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 12: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: worst‐case scenario" data-id="CD013066-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 12: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: worst‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 13: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: the Gamble‐Hollis analysis" data-id="CD013066-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 13: Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: the <i>Gamble‐Hollis analysis</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 14: Severe adverse events" data-id="CD013066-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 14: Severe adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 15: Non‐severe adverse events" data-id="CD013066-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 15: Non‐severe adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 16: Functional recovery: assessed with the Barthel Index" data-id="CD013066-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 16: Functional recovery: assessed with the Barthel Index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013066-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/urn:x-wiley:14651858:media:CD013066:CD013066-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citicoline versus placebo or not intervention, Outcome 17: Patients with minor impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale)" data-id="CD013066-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_t/tCD013066-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Citicoline versus placebo or not intervention, Outcome 17: Patients with minor impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/media/CDSR/CD013066/image_n/nCD013066-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013066-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Citicoline compared with placebo or standard treatment for treating people with acute ischemic stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Citicoline compared with placebo or no intervention for treating people with acute ischemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acute ischemic stroke<br/><b>Settings:</b> either inpatients or outpatients<br/><b>Intervention:</b> citicoline<br/><b>Comparison:</b> placebo or standard treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Citicoline</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality (at any time of trial)</b><br/>Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>162 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/>(135 to 173) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.83 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4362<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability or dependence in daily activities</b> </p> <p>Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale) </p> <p>lower scores indicate better outcome</p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/>(219 to 284) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/>(0.97 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3668<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe adverse events</b> <br/>Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>166 per 1000</b><br/>(134 to 205) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/>(1.00 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3591<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This information corresponds to pooled analysis for the risk of severe cardiovascular adverse events. Trials reported number of adverse events instead of number of participants with adverse events. See <a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional recovery</b><br/>Patients with scores in the Barthel Index ≥ 95 points<br/>Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b><br/>(316 to 380) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/>(0.94 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3850<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a> reported this outcome using 50 points </p> <p><a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a> reported it with a range of points (85 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological function</b><br/>Patients with minor impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale)<br/>Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>244 per 1000</b><br/>(217 to 274) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/>(0.96 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3950<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (at the time of follow‐up)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trials assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Assumed risk is based on median control group risks in the meta‐analysis.<br/><sup>b</sup>Downgraded 2 levels for limitations in design and execution: 88% (7/8) of the trials assessing this outcome had high risk for allocation, and 38% (3/8) showed high risk for attrition bias for this outcome.<br/><sup>c</sup>Downgraded 2 levels for limitations in design and execution: 75% (3/4) of the trials assessing this outcome had high risk for allocation, and 50% (2/4) showed high risk for attrition bias, and 75% (3/4) had high risk for detection bias for this outcome.<br/><sup>d</sup>Dowgraded 2 levels due to high risk of bias and imprecision (small number of events).<br/><sup>e</sup>Downgraded 2 levels for limitations in design and execution: 75% (3/4) of the trials assessing this outcome had high risk for allocation, and 75% (3/4) showed high risk for detection bias for this outcome.<br/><sup>f</sup>Downgraded 2 levels for limitations in design and execution: 80% (4/5) of the trials assessing this outcome had high risk for allocation, and 40% (2/5) showed high risk for attrition bias, and 75% (3/4) had high risk for detection bias for this outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Citicoline compared with placebo or standard treatment for treating people with acute ischemic stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013066-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐analyses with 95% CI using either a fixed‐effect or random‐effects model results</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fixed‐effect</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Random‐effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.94, 95% CI 0.83 to 1.07; I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.94, 95% CI 0.83 to 1.07; I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Degree of disability or dependence in daily activities according to the modified Rankin scale </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11, 95% CI 0.97 to 1.26; I² = 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11, 95% CI 0.97 to 1.26; I² = 1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe adverse events (Reporting cardiovascular adverse events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.04 95% CI 0.84 to 1.29; I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.04 95% CI 0.84 to 1.28; I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Functional recovery: assessed with the Barthel Index (≥95 points)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.03, 95% CI 0.94 to 1.13; I² = 24%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05, 95% CI 0.93 to 1.17; I² = 24%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological function assessed with the National Institutes of Health Stroke Scale (NIHSS):≤1 points) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.08, 95% CI 0.96 to 1.21; I² = 27%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.09, 95% CI 0.93 to 1.27; I² = 27%</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐analyses with 95% CI using either a fixed‐effect or random‐effects model results</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013066-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Included trials: description of the harms</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Harms</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "A patient in the active group with a history of gastric ulcer presented a digestive bleeding and the treatment was discontinued; no adverse effects were reported in the placebo group." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "Only two adverse events were seen seen in greater incidence in the citicoline group: edema of the extremities ( p ≤ 0.05) and back pain (p ≤ 0.10)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "In addition it was tolerated very well."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriate report (<a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See <a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a> for severe adverse events<br/>Quote: "No serious adverse effects were related to treatment with CDP‐choline in any patient with cerebral infarction." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "There were no serious adverse events reasonably attributed to the study medication. The only adverse events that were significantly different between the treatment groups and placebo group were dizziness and accidental injury, primarily related to falling. Of the patients who fell, only one (2000 mg group) was of clinical significance (associated with hip fracture), whereas the remainder were minor in nature. It should be noted that the patients who were experiencing dizziness were not the same patients who experienced accidental injuries." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriate report (<a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriate report (<a href="./references#CD013066-fig-0019" title="">Analysis 1.14</a>) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Included trials: description of the harms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013066-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sample size estimation a priori and trial's conclusions</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sample size estimation a priori/randomized participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of reported outcomes/number of comparison groups</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prefixed primary outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Was clinical primary</b> <b>outcome?</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Statistical power</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Alpha</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Type of statistical test (1‐tailed or 2‐tailed)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial's conclusions</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0001" title="AlvairezE , GonzalezM . Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double-blind study compared with placebo [Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo]. Archivos Venezolanos de Farmacología y Terapéutica2007;26(2):127-30. [ISSN 0798-0264]">Alviarez 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "The Citicholine was superior to placebo to improve the percentage of patients that can be assisted to if same after an episode of ictus acute, taken place by the occlusion of the cerebral media artery." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0010" title="WarachS , PettigrewLC , DasheJF , PullicinoP , LefkowitzDM , SabounjianL , Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology2000;48(5):713-22. [PMID: 11079534]">Warach 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (with multiple correlations)/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "We found a significant inverse relationship between lesion volume change over 12 weeks as measured by MRI and clinical outcome for ischemic stroke. This relationship supports the role of DWI as a surrogate marker of clinically meaningful lesion progression in stroke clinical trials. The hypothesis that citicoline reduces lesion growth and improves clinical outcome will be tested further." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "It was recognized that this study would be underpowered to<br/>detect a difference in clinical outcome." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0005" title="GhoshS , DasSK , NathT , GhoshKC , BhattacharyyaR , MondalGP . The effect of citicoline on stroke: a comparative study from the Eastern part of India. Neurology India2015;63(5):697-701. [PMID: 26448227]">Ghosh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Treatment with citicoline in patients of stroke, presenting within 48 h of onset, increases the probability of recovery and a favorable outcome at the end of the 1<sup>st</sup> and the 3<sup>rd</sup> month in all stroke groups. A large randomized control trial is necessary in near future to support the results of this study." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0006" title="GuillenF , BuendiaC , HerreraJ . CDP-choline in the treatment of acute ischaemic stroke. Journal of Neurology1995;242 Suppl 2:S76. ">Guillen 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "CDP‐choline seemed better than the placebo, leading to improvement as quantified by the GCS (p&lt;.05), Mathew's Scale (p&lt;:01), Barthel's Scale (p&lt;.05) and the Red Cross Scales (p&lt;.05)." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0007" title="DávalosA , Alvarez-SabínJ , CastilloJ , Díez-TejedorE , FerroJ , Martínez-VilaE , International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet2012;380(9839):349-57. [PMID: 22691567]">ICTUS 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Under the circumstances of the ICTUS trial, citicoline is not efficacious in the treatment of moderate to‐ severe acute ischaemic stroke." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0008" title="SeifaddiniR , MoghadamAH , IranmaneshF , ArvanH , Naghibzadeh-TahamiA . The effects of citicoline on cerebrovascular hemodynamic status in ischemic stroke patients. Journal of Kerman University of Medical Sciences2017;24(6):480-6. ">Seifaddini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Prescription of citicoline for treatment of acute ischemic stroke is associated with hemodynamic changes in cerebral arteries. This finding can be one of the citicoline's mechanisms of action in ischemic stroke process." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0009" title="TazakiY , SakaiF , OtomoE , KutsuzawaT , KameyamaM , OmaeT , et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke1988;19(2):211-6. [PMID: 3278412]">Tazaki 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "The group treated with CDP‐choline showed significant improvements in level of consciousness compared with the placebo‐treated group, and CDP‐choline was an entirely safe treatment." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0002" title="ClarkWM , WarachSJ , PettigrewLC , GammansRE , SabounjianLA , Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology1997;49(3):671-8. [PMID: 9305321]">Clark 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No/259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0003" title="ClarkWM , WilliamsBJ , SelzerKA , ZweiflerRM , SabounjianLA , GammansRE . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke1999;30(12):2592-7. [PMID: 10582983]">Clark 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "The results of this study indicate that citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke who were enrolled in this trial." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013066-bbs2-0004" title="ClarkWM , WechslerLR , SabounjianLA , SchwiderskiUE . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology2001;57(9):1595-602. [PMID: 11706098]">Clark 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>DWI: diffusion‐weighted magnetic resonance imaging<br/>GCS: Glasgow Coma scale.<br/>MRI: magnetic resonance imaging<br/>NA: not applicable </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sample size estimation a priori and trial's conclusions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/full#CD013066-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013066-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Citicoline versus placebo or not intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Citicoline 500 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.70, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Citicoline 1000 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.22, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Citicoline 500, 1000 or 2000 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.52, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Citicoline 2000 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality: subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Trials without support by pharmaceutical companies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.41, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Trials supported by pharmaceutical companies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality: subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Trials with ≤ 200 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.70, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Trials with &gt; 200 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality: sensitivity analysis: impact of missing outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Trials non‐reporting missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.79, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Trials reporting missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.78, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause mortality: sensitivity analysis: best‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Trials without missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.80, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Trial with missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.37, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 All‐cause mortality: sensitivity analysis: worst‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Trials without missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.79, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Trial with missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.79, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 All‐cause mortality: sensitivity analysis: the <i>Gamble‐Hollis</i> analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Trials without missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.79, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Trial with missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.45, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.97, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.97, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Trials with ≤ 200 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.67, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Trials with &gt; 200 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.96, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: impact of missing outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Trials without missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.01, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Trials with missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.87, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: best‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Trial without missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.00, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Trial with missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.39, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: worst‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Trial without missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.00, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Trial with missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [2.03, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Patients with moderate or lower degree of disability or dependence (according to &lt; 3 scores in the modified Rankin scale): sensitivity analysis: the <i>Gamble‐Hollis analysis</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Trial without missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.00, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Trial with missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.54, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Cardiovascular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.84, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Central nervous system (including hemorrhagic or ischemic stroke)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.07, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Respiratory (including pneumonia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.78, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 Gastrointestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.40, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.5 Musculoskeletal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.50, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.6 Hepatic dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.18, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.7 Renal and urologic disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.99, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.8 Hematological disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.46, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Non‐severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Cardiac disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.82, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.88, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.4 Urinary tract infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.89, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.6 Nausea and vomiting symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.7 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.94, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.8 Hemorrhagic transformation stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.9 Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.73, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.10 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.63, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Functional recovery: assessed with the Barthel Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 50 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.71, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 ≥ 95 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 85 to 100 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [1.10, 8.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Patients with minor impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Citicoline versus placebo or not intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013066.pub2/references#CD013066-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013066.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013066-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013066-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013066-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013066-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013066-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013066-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013066-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013066-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013066-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013066\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013066\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013066\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013066\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013066\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013066.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013066.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013066.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013066.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013066.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714178110"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013066.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714178114"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013066.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6842a868937d',t:'MTc0MDcxNDE3OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 